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Abstract 
Bovine respiratory disease (BRD) remains a major disease in beef production systems.  The 
administration of antimicrobials for both the control and treatment of acute BRD is common. 
According to most published accounts, antimicrobial resistance among BRD pathogens is 
increasing; therefore, judicious antimicrobial usage is vital for continued efficacy. The 
introduction of a novel antimicrobial class has not occurred for well over a decade, therefore it is 
paramount to maximize efficacy of the antimicrobials currently available. The challenge is 
targeting the perfect scenario: maximizing clinical efficacy while minimizing antimicrobial 
resistance. The host-pathogen-drug interaction is very complex and despite current sophisticated 
technology, this interaction is still not well understood for many infectious diseases.  
This dissertation work sought to investigate the effects of the administration of a macrolide 
for both control and treatment of acute BRD on the prevalence of resistance among isolated 
Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Whole genome 
sequencing of M. haemolytica was utilized to investigate the presence/absence of macrolide 
resistance genes and their relationship to the observed minimum inhibitory concentration. Cattle 
were sampled (plasma and pulmonary epithelial lining fluid) after administration of 
gamithromycin for drug concentration analysis. A non-linear mixed effects approach was used to 
fit a compartmental model to the resulting sparse pharmacokinetic data so that a complete time 
concentration curve could be simulated. From these curves, the CMAX and AUC were measured 
and used to calculate standard PKPD indices using the MIC values of the isolated bacteria. 
Clear associations between the use of gamithromycin for control and treatment of BRD 
and a statistically significantly increased likelihood of macrolide resistance were not found, 
possibly due to sample size limitations. The calculation of pharmacokinetic-pharmacodynamic 
  
indices found that a longer drug exposure was more closely associated with a successful treatment 
outcome, but there was not a statistically significant correlation. However, there were few clinical 
failures in this study giving further credence to the complexity of the in vivo system. There are 
many factors beyond pharmacokinetics/pharmacodynamics and MICs that contribute to the 
success of a treatment regimen for cattle suffering from BRD. 
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gamithromycin for drug concentration analysis. A non-linear mixed effects approach was used to 
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concentration curve could be simulated. From these curves, the CMAX and AUC were measured 
and used to calculate standard PKPD indices using the MIC values of the isolated bacteria. 
Clear associations between the use of gamithromycin for control and treatment of BRD 
and a statistically significantly increased likelihood of macrolide resistance were not found, 
possibly due to sample size limitations. The calculation of pharmacokinetic-pharmacodynamic 
  
indices found that a longer drug exposure was more closely associated with a successful treatment 
outcome, but there was not a statistically significant correlation. However, there were few clinical 
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 Abstract 
Bovine respiratory disease (BRD) remains a major disease both from an economic and an animal 
welfare standpoint in beef production systems.  Antimicrobial administration is a mainstay in both 
the control of and in the therapeutic treatment of acute BRD.  However, the pipeline of novel 
antimicrobial classes has remained dry for well over a decade.  Therefore, the judicious use of 
antimicrobials in both human and animal health remains paramount to ensure efficacy of treatment 
remains acceptable.  In order to judiciously prescribe antimicrobials the clinician needs to have an 
understanding of reasonable expectations for antimicrobial efficacy in the treatment and control of 
clinical disease.  As such, a systemic review was conducted in the scientific literature including 
the Freedom of Information Summaries of New Animal Drug Approvals on the FDA website.  The 
objective of this article was to present a cumulative review of the data from published randomized 
clinical trials utilizing a negative control in the treatment and control of BRD using the number 
needed to treat as a means to effectively convey this information to the bovine practitioner. 
 Key Points 
 The randomized clinical trial (RCT) is the gold standard for efficacy determination 
 RCTs with negative (no treatment) controls are not clouded by a control group treatment 
effect 
 Absolute risk reduction (ARR) is the difference in the probabilities of an event in the 
control and treatment groups and is estimated as the corresponding difference in the event 
rates 
 Number needed to treat (NNT) is the reciprocal of the ARR 
 NNT is more clinically intuitive as it describes the effect in terms of the number of patients 
a clinician needs to treat to expect a given (typically positive) outcome  
 Outline 
 Introduction 
 External validity of clinical trials 
 Ancillary therapy use in BRD 
 Antimicrobial use in BRD 
 Material and Methods 
3 
o Search Strategy and Inclusion Criteria 
o Article Exclusions 
o Data Extraction 
 Results 
o The Effects of Antimicrobials 
o Number Needed to Treat 
 Discussion 
 
 Introduction 
Bovine respiratory disease (BRD) is a multi-factorial disease that has been well described by many 
researchers as a complex or syndrome involving an interaction of stressors, viruses, and bacteria.  
Despite decades of dedicated research, BRD remains a major disease in all types of beef and dairy 
production systems with an estimated global economic impact in excess of $3 billion/year.1  
Antimicrobial administration is a mainstay in both the control of disease in populations at high 
risk of BRD and in the therapeutic treatment of acute clinical disease.  However, the pipeline of 
novel antimicrobial classes for the therapy of BRD has remained dry since the introduction of 
enrofloxacin (Baytril 100®, Bayer Animal Health, Shawnee Mission, KS) in 1998.  Therefore, the 
judicious use of antimicrobials in both human and animal health remains paramount to ensure 
efficacy of treatment remains acceptable.   
The objective of this chapter is to evaluate the use of antimicrobials for the therapy of bovine 
respiratory disease through the lens of a cumulative review of published randomized clinical trials 
investigating the effects of an antimicrobial drug for treatment or control of BRD against a negative 
control.  The number needed to treat NNT will be used to describe these trials.2  There are 
numerous ways to express the value of an active treatment over that of its control group, such as 
odds ratios and risk reduction.  Number needed to treat is the reciprocal of the absolute risk 
reduction which is the difference in the probabilities of an event in the control and treatment 
groups, and is estimated as the corresponding difference in these event rates.   The NNT statistic 
4 
has the one major advantage of being more straightforward to readers less versed in thinking of 
events (clinical outcome) in terms of probabilities.  As such, NNT is much easier interpreted by 
the practicing clinician and speaks in terms of number of treatments needed to make a difference 
in one patient.  The use of NNT, by expressing the effect of the drug in relation to disease recovery 
of negative controls over the same period, also incorporates the severity of the disease challenge 
into the estimate of drug effect.  Therefore, the use of the NNT value must be carefully relegated 
to the disease, regimen, animal species, and the specific disease challenge.   
 Ancillary Therapy Use in BRD 
A systematic review was conducted and published in 2012 by Francoz et al. on the use of ancillary 
drugs in the treatment of BRD.3  While finding very little reliable and consistent data, they did 
conclude that there were not enough data at that time to recommend the use of any ancillary therapy 
alongside antimicrobials in the treatment of BRD.  Using the same search criteria as performed in 
that study we were unable to identify any recent publications of relevance to expanding that 
conversation, therefore interested readers should consult that publication.   Likewise, no clinical 
trial data addressing the use of more than one antimicrobial at a time vs. a single antimicrobial for 
the therapy of BRD was found. The focus of this review is therefore limited to the use of 
antimicrobials alone in the treatment of BRD. 
 Antimicrobial use in BRD 
The prospective, masked, randomized clinical trial conducted in naturally occurring disease is the 
gold standard for the evaluation of efficacy for disease intervention in both human and veterinary 
medical clinical research. In regard to naturally occurring BRD studies of antimicrobial efficacy, 
the literature can be divided into those utilizing a negative control and those comparing the test 
article to a positive control.  When using a positive control treatment, the goal of the experiment 
5 
is to prove either superiority or non-inferiority, either of which require quite different study 
designs.  The lack of a significant difference in treatment outcomes in a trial which was not 
adequately designed to demonstrate non-inferiority cannot necessarily be interpreted as 
equivalence of the treatments.  Analysis and interpretation of trials with positive controls provides 
many challenges and is beyond the scope of this article.  An excellent meta-analysis was recently 
performed in this area and readers wishing for that scope should refer to the article by O’Connor 
et al.4  However, a brief comparison of their approach and objectives to those of this report will be 
offered in the following paragraph. 
O’Connor et al. used a mixed treatment comparison meta-analysis to compare the efficacy of 
antimicrobial treatments for BRD.5  In addition to including trials utilizing a negative control, their 
inclusion criteria and methods of analysis allowed the inclusion of study designs utilizing a 
positive control as a treatment arm in their analysis.  As such the number of article inclusions was 
much larger than those included in this report.  In Figure 1, reproduced with permissions, a visual 
network of the treatment arms compared in their meta-analysis can be appreciated.  Their 
publication offered comparisons of 60 trials of active drug to negative controls (including FOIs) 
and 33 comparisons of active to active (one antimicrobial to another) controls.  By means of their 
type of meta-analysis method they were able to rank antimicrobial treatments of BRD by efficacy 
(Figure 2).  Using their rankings, it can be seen that with the published data available in the 
literature, tulathromycin ranks as the most efficacious treatment for BRD and the older molecules 
such as the ceftiofur formulations, trimethoprim and oxytetracycline are among the least 
efficacious antimicrobial treatments for BRD.  However, as pointed out by O’Connor et al. one 
limitation not unique to their meta-analysis, is that the analysis is limited to those data publically 
available.  If more privately held trial data were offered, better estimates might be possible. 
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In this chapter, we have not attempted to include those publications with a positive control as we 
are not attempting to compare efficacy between treatments, instead we wish to eludicate the actual 
effect gained from the use of an antimicrobial in therapy or control of BRD.   As such, a simplified 
interpretation of results is possible when the control group is administered either no treatment or a 
sham such as a saline injection, since comparisons to the control group are not clouded by an actual 
treatment effect.  It is in this type of research where the true effect of the antimicrobial, in that 
population of cattle, can be discerned.  A certain level of spontaneous recovery is expected, either 
due to misdiagnosis, a fully competent and successful immune response, or other factors that are 
unidentifiable.  Therefore, comparing treated to untreated controls using the NNT allows an easily 
interpreted measurement of the antimicrobial effect in a specific clinical situation that can be 
readily comprehended by veterinary practitioners and their clients alike. 
 Deciding what data drives decisions 
 A systematic review of the literature was performed using the online resources PubMed 
and Web of Knowledge in August of 2014 with similar search terms as outlined previously.4  
Studies were limited to those published in English and originating from North America.  Criteria 
for inclusion in this review were that the publications must have been investigations into the 
treatment or control of BRD with an antimicrobial in a randomized, blinded, negative control field 
trial study design where subjective evaluators were masked and the disease was naturally 
occurring.  Trials had to involve the administration of a single antimicrobial, with no ancillary 
therapy, either for treatment of naturally occurring BRD or in the control of naturally occurring 
BRD.  Studies on the treatment of naturally occurring BRD must have involved animals that were 
not treated for control of BRD with an antimicrobial prior to or as part of the study.  All trials 
involving positive controls or experimental challenge models were excluded.  Additionally, 
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publications were screened to ensure that they were not duplicative of FOI data, as was the case 
on many occasions.  
Additionally, the Freedom of Information (FOI) New Animal Drug Approvals (NADA) 
summaries were searched on the FDA website at the same time.  Inclusions from the FOI 
summaries include efficacy trials (ET), dose response studies (DRS), dose selection studies (DSS), 
single location field studies (FS), and multi-location field studies (MLFS).  The only arms of dose 
selection studies reported here are those which used current labeled dosages in the trial. 
 Article Exclusions 
Notably, articles from Hibbard et al. and Hamm et al., which have been included in other review 
articles on antimicrobial treatment of BRD, were not included in this analysis as they were both 
found to be publications of data from their NADA FOI summaries.6,7  Additionally, in the Hibbard 
et al. article the third trial was not included in the control analysis because the allocation to each 
treatment group was not presented. Percentages were given in tables of the trial outcome but did 
not allow the calculation of confidence intervals.  An article from Messersmith et al. was not 
included because there was no mention of blinding the evaluators and in the article they actually 
mention tagging animals in accordance with their treatment which would suggest that evaluating 
investigators were aware of treatment during evaluation.8  
 Data Extraction 
Articles were organized by those investigations of BRD treatment efficacy or those reporting on 
efficacy of treatment for control of BRD.  Outcome measures of treatment efficacy papers were 
treatment failures and mortality, those measurements in the control papers were morbidity.  A 
summary of the individual animal treatment studies included in this report are included in Table 
1.  All NADA approval studies are listed by pharmaceutical company currently holding rights to 
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the drug.  The published journal articles are listed by the name of the company as it was when the 
study was supported and published.  Table 2 includes the publications providing data for the 
control/prevention portion of the analysis.   
General information from FOI summaries and study reports were gathered including authors, 
publication source, pharmaceutical sponsorship, treatment regimen, number of animals per 
treatment group, and treatment outcomes. 
 The Effect of Antimicrobials in Treating and Controlling BRD 
The box plots in Figures 1, 2, and 3 represent a grouping of all the studies in regard to the trial 
outcomes of those animals receiving antimicrobials versus those receiving no treatment.  A median 
spontaneous recovery rate of 24% was found across all trials in the control group versus a 71% 
recovery rate of those treated with active ingredient for the therapeutic trials (Figure 1).  This 
indicates an increase of 47% recovery rate with the use of antimicrobials as compared to a negative 
control.  The median mortality rates by treatment group are 1% and 17% in treated and negative 
controls, respectively (Figure 2).  The impact of treatment for control of BRD with an approved 
antimicrobial in cattle at high risk for developing disease can be seen in Figure 3.  Treatment for 
control of BRD decreased the incidence of morbidity by more than half in these populations of 
cattle (22% in treated cattle versus 48% incidence in control cattle). 
 Number Needed to Treat 
Using the extracted data, a spread sheet was constructed in Microsoft Excel (2013) with the 
information in Tables 1 and 2 along with the outcomes of each individual trial.  Absolute risk 
reduction, number needed to treat and their respective 95% confidence intervals were calculated 
with the use of a spreadsheet calculator developed utilizing the Newcombe-Wilson method without 
continuity correction.9  The outputted ARR and confidence intervals were inputted into JMP 11.0.0 
9 
(SAS Institute, Cary, NC) for the creation of forest plots.  Next, an additional axis for NNT was 
manually added to each forest plot as described previously by Altman.10   
Those trials that have confidence intervals crossing the null axis (dashed line at 0 and ∞) display 
insignificant results.  Meaning, that it cannot be stated with 95% confidence that the use of that 
drug, in that group of cattle, had a positive effect compared to treatment with saline sham injection.   
It should be pointed out that each of the antimicrobials reported with insignificant confidence 
intervals in this report were shown to have substantial evidence of clinical efficacy by different 
statistical tests of significance, as can be found in each of their respective FOIs.  Confidence 
interval estimation for the comparison of two proportions is not without its drawbacks, including 
the creation of intervals that do not make logical sense, termed aberrations, and an achieved 
confidence level that can be quite different than the intended 1-α.9  However, the method used in 
this paper performs well with large sample sizes and is less affected by unequal sample sizes as 
compared to many other methods.11 
As discussed by Altman, trials resulting in ARR lower confidence intervals that are negative 
present a problem when presenting data as the NNT.  The inverse of a very small negative number 
is another larger negative number which is completely illogical, clinically.  As an example, the 
reciprocal of the ARR 95% lower confidence interval of Ceftiofur sodium, 1.1 mg/kg, 
intramuscularly daily for 3 days (DSR1) in Figure 4 is -438, which by definition means that -438 
animals would need to be treated to have a positive outcome in one case.  While this makes little 
clinical sense, it also presents a problem when graphing these data.  The solution is to think of this 
in terms of that the drug has no effect or an infinite number of animals could be treated without 
seeing a positive outcome due to the antimicrobial, as can be seen graphically in Figures 4, 5, and 
6. 
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The overwhelming majority of trials show a positive effect on case outcome in the therapy and 
control of BRD.  The median NNT in therapeutic trials involving negative controls is 2.  Therefore, 
for every 2 animals treated for BRD in the overall population of these studies, one case was a 
treatment success, seen in the last row of Figure 4 (labeled Median).  The median NNT for 
preventing one mortality due to BRD in the trials reviewed is 6; for every 6 animals treated, 
therapeutically, 1 BRD death is prevented displayed in Figure 5.  In Figure 6, for BRD control 
studies, the median number of animals that need to be treated to prevent one acute case of BRD is 
5. 
 External validity of the included trials 
The vast majority of the clinical trial data used in this review were generated in what would be 
classified as “high risk” calves where significant morbidity is expected due to comingling and 
accumulated stress, plus the lack of optimal vaccination or nutritional protocols in many cases.  
Therefore, application of these NNT values to low risk calves, yearling cattle, or cows would be 
inappropriate other than as a very general indication of potential effects.  
  Other key determinants of external validity are the study entrance and success/failure 
criteria.  These are summarized for the referenced sources of clinical trial data in Table 3.  It is 
apparent that the case definitions for both study entrance and success/failure vary by study.  We 
would also expect interpretation of the criteria to vary by investigator.  In the opinion of the second 
author, the case definitions for success required to achieve concurrence with the FDA Center for 
Veterinary Medicine on pivotal clinical trial protocols are likely to result in a lower success rate 
than would criteria commonly applied in commercial settings.  While this may still result in valid 
testing when applied to all treatments, there is the potential for being overly conservative when 
estimating the effect of these antimicrobials in a commercial setting.   
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 Discussion 
The objective of this article was to explore the effectiveness of antimicrobials in the therapy and 
control of BRD as compared to no treatment.  Extreme caution should be taken in directly 
comparing the NNT of one antimicrobial to another due to differences in trial design, sample size 
discrepancies, risk classification differences of BRD between trials, resultant spontaneous 
recovery rates, and potential differences in case definition and success/failure outcome between 
trials.  However, in the author’s opinion since a bulk of the data come from FOI summaries a 
majority of the variables (population risk status, case and success/failure definitions) are very 
similar and provide a much better means of comparison than meta-analysis of trials utilizing 
positive treatment controls.   
The presentation of the data in this manner also makes for a succinct way of defining reasonable 
expectations of efficacy in the treatment and control of BRD in a field setting for cattle at high risk 
of BRD.  It should be pointed out once again that the clinician interpreting these data needs to bear 
in mind the external validity of these studies when applying it to the type of cattle, environmental 
setting and typical BRD pathogens encountered in their practice.  
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 Figures and Tables 
Author Citation Antimicrobial Date 
Pharm 
Sponsor 
Study 
Length 
(days) 
Tot
al N 
Mortality 
Reported 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 84 Yes 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 88 Yes 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 88 Yes 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 88 Yes 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 88 Yes 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 405 Yes 
NADA 140-
338 
12 Ceftiofur 
Sodium 
Approved 
1988 
Zoetis 28 405 Yes 
NADA 141-
063 
13 Florfenicol Approved 
1996 
Merck 28 50 Yes 
NADA 141-
063 
13 Florfenicol Approved 
1996 
Merck 15 95 Yes 
NADA 141-
063 
14 Florfenicol Approved 
1998 
Merck 12 75 Yes 
NADA 141-
063 
14 Florfenicol Approved 
1998 
Merck 12 75 Yes 
NADA 141-
063 
14 Florfenicol Approved 
1998 
Merck 11 150 Yes 
NADA 141-
063 
14 Florfenicol Approved 
1998 
Merck 11 150 Yes 
NADA 141-
209 
15 Ceftiofur CFA Approved 
2003 
Zoetis 14 108 No 
NADA 141-
068 
16 Enrofloxacin Approved 
1996 
Bayer 15 24 Yes 
NADA 141-
068 
16 Enrofloxacin Approved 
1998 
Bayer 15 24 Yes 
NADA 141-
068 
16 Enrofloxacin Approved 
1996 
Bayer 28 445 Yes 
NADA 141-
068 
16 Enrofloxacin Approved 
1998 
Bayer 28 145 Yes 
NADA 141-
068 
16 Enrofloxacin Approved 
1996 
Bayer 28 456 Yes 
NADA 141-
068 
16 Enrofloxacin Approved 
1998 
Bayer 28 152 Yes 
13 
NADA 141-
207 
17 Danofloxacin Approved 
2002 
Zoetis 10 238 Yes 
NADA 141-
244 
18 Tulathromyci
n 
Approved 
2005 
Zoetis 14 474 Yes 
NADA 141-
328 
19 Gamithromyci
n 
Approved 
2011 
Merial 10 497 No 
NADA 141-
328 
19 Gamithromyci
n 
Approved 
2012 
Merial 10 242 No 
NADA 141-
328 
19 Gamithromyci
n 
Approved 
2012 
Merial 10 260 No 
NADA 141-
334 
20 Tildipirosin Approved 
2012 
Merck 14 600 Yes 
NADA 141-
207 
21 Danofloxacin Approved 
2011 
Zoetis 10 240 No 
NADA 141-
265 
22 Florfenicol Approved 
2008 
Merck 11 244 No 
Kilgore et al. 23 Tulathromyci
n 
Published 
2005 
Pfizer 14 480 Yes 
Kilgore et al. 23 Tilmicosin Published 
2005 
Pfizer 14 480 Yes 
Booker et al. 24 Florfenicol 
Published 
1997 
Schering-
Plough 
45 125 Yes 
Table 1.1- Outline of publications presented for analysis in the therapy of bovine respiratory 
disease in cattle from studies in North America.  Pharmaceutical sponsors are listed by name as it 
exists today for each of the New Animal Drug Application (NADA) studies. Where applicable, 
pharmaceutical companies are listed as they were named when sponsoring the independently 
published research studies. 
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Author 
Citatio
n 
Antimicrobia
l 
Date 
Pharma 
Sponsor 
Study 
Length 
(days) 
Tota
l  
N 
NADA 141-209 15 Ceftiofur 
CFA 
Approved 
2003 
Zoetis 29 1504 
NADA 141-244 18 Tulathromyc
in 
Approved 
2005 
Zoetis 14 799 
NADA 141-063 14 Florfenicol Approved 
1998 
Merck 28 399 
NADA 141-063 14 Florfenicol Approved 
1998 
Merck 28 198 
NADA 141-143 25 Oxytetracycl
ine 
Approved 
2003 
Norbroo
k 
30 1199 
NADA 141-143 25 Oxytetracycl
ine 
Approved 
2003 
Norbroo
k 
30 1200 
NADA 140-929 26 Tilmicosin Approved 
1996 
Elanco 28 707 
NADA 141-328 19 Gamithromy
cin 
Approved 
2011 
Merial 10 159 
NADA 141-328 19 Gamithromy
cin 
Approved 
2011 
Merial 10 308 
NADA 141-334 20 Tildipirosin Approved 
2012 
Merck 14 773 
Kilgore et al. 27 Tulathromyc
in 
Published 
2005 
Pfizer 14 819 
Kilgore et al. 27 Tilmicosin Published 
2005 
Pfizer 14 817 
Galyean et al. 28 Tilmicosin Published 
1995 
none 28 57 
Galyean et al. 28 Tilmicosin Published 
1995 
none 28 116 
Galyean et al. 28 Tilmicosin Published 
1995 
none 56 121 
Vogel et al. 5 Tilmicosin Published 
1998 
Elanco 28 1096 
Johnson et al. 29 Ceftiofur 
CFA 
Published 
2008 
Pfizer 69-83 1045 
Hendrick et al. 30 Oxytetracycl
ine 
Published 
2013 
Merck 24-49 3784 
Table 1.2 - Outline of publications presented for analysis in the control/prevention of bovine 
respiratory disease in cattle from studies in North America. Pharmaceutical sponsors are listed by 
name as it exists today for each of the New Animal Drug Application (NADA) studies. Where 
applicable, pharmaceutical companies are listed as they were named when sponsoring the 
independently published research studies. 
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Figure 1.1  The network of treatment arms used in O’Connor et al. mixed treatment comparisons 
met-analysis. The size of the dot is a relative indicator of the number of arms and the width of the 
lines is a relative indicator of the number of direct comparisons (number of arms).  Reproduced 
with permission from Elsevier.  
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Figure 1.2– Ranking forest plot for treatment arms in O’Connor et al. mixed treatment comparison 
meta-analysis of antibiotic protocols for BRD (mean rank and 95% credibility interval).  
Reproduced with permission from Elsevier. 
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Figure 1.3 - Treatment success rate in all trials included in the therapeutic portion of the analysis.  
Control (CON) animals received either no treatment or sham-saline injection, treated (TRT) 
animals received an antimicrobial for the treatment of acute bovine respiratory disease. 
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Figure 1.4 - Mortality incidence rates in all trials included in the therapeutic portion of the analysis.  
Control (CON) animals received either no treatment or sham-saline injection, treated (TRT) 
animals received an antimicrobial for the treatment of acute bovine respiratory disease. 
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Figure 1.5 - Morbidity incidence rates in all trials included in the mass medication portion of the 
analysis.  Control (CON) animals received either no treatment or sham-saline injection, treated 
(TRT) animals received an antimicrobial for the prevention/control of bovine respiratory disease. 
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Figure 1.6 - Forest plot of point estimates and 95% confidence intervals of the Absolute Risk 
Reduction of morbidity (bottom x-axis) and the corresponding Number Needed to Treat (top x-
axis) found from analysis of the therapeutic studies.  Studies listed on the y-axis correspond in 
order to those listed in Table 1 and are listed by active ingredient, dose (mg/kg), route of 
administration and duration of therapy. (ET = efficacy trial, DRS = dose response study, CT = 
clinical Trial, FS = field study, DSS = dose selection study, MLFS = multi-location field study) 
21 
 
Figure 1.7- Forest plot of point estimates and 95% confidence intervals of the Absolute Risk 
Reduction of mortality (bottom x-axis) and the corresponding Number Needed to Treat (top x-
axis) found from analysis of the therapeutic studies.  Studies listed on the y-axis correspond in 
order to those listed in Table 1 and are listed by active ingredient, dose (mg/kg), route of 
administration and duration of therapy. (ET = efficacy trial, DRS = dose response study, CT = 
clinical Trial, FS = field study, DSS = dose selection study, MLFS = multi-location field study) 
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Figure 1.8 - Forest plot of point estimates and 95% confidence intervals of the Absolute Risk 
Reduction (bottom x-axis) and the corresponding Number Needed to Treat (top x-axis) found from 
analysis of the control studies.  Studies listed on the y-axis correspond in order to those listed in 
Table 1 and are listed by active ingredient, dose (mg/kg), route of administration and duration of 
therapy. (ET = efficacy trial, DRS = dose response study, CT = clinical Trial, FS = field study, 
DSS = dose selection study, MLFS = multi-location field study) 
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 Abstract 
The objective of this manuscript was to perform a critical review of the literature as it pertains to 
the current status of antimicrobial resistance in pathogens associated with bovine respiratory 
disease (BRD) in beef cattle and to provide a concise yet informative narrative on the most relevant 
publications available. As such the scientific literature contained in PubMed, AGRICOLA, and 
CAB were searched in February of 2014 for articles related to susceptibility testing of Mannheimia 
haemolytica, Pasteurella multocida and Histophilus somni from cases of BRD. Titles and abstracts 
were read and 105 articles that were relevant to the subject of BRD antibiotic resistance were 
attained for further review. After the application of exclusion criterion (publications must have 
originated from North America, be in English, adhere to standards set forth by the CLSI, and be 
concerning antimicrobial resistance in BRD in beef cattle), 16 articles remained and are the focus 
of this publication. Due to the disparate data from the few studies that investigate susceptibility 
testing of BRD pathogens, a quantitative assessment or meta-analysis was not performed on the 
studies presented in this review. However, considering diagnostic lab data, there appears to be a 
clear trend of a decrease in susceptibility of the three major BRD pathogens to the antimicrobials 
used commonly for treatment and control of BRD. Studies performing sensitivity testing on 
healthy cattle report much lower resistance, but it remains unclear if this is because of a true lack 
of resistance mechanisms, or if the isolates do contain quiescent genes for resistance that are only 
phenotypically expressed following the administration of an antimicrobial for either treatment or 
control of bovine respiratory disease. Future research to address this question of genotype and 
phenotypic expression before and after antimicrobial administration will further advance our 
knowledge in this area. 
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 Introduction 
Bovine respiratory disease (BRD) is a multi-factorial disease complex involving an interaction of 
stressors (weaning, passage through auction markets, commingling, shipping, etc.), viral infections 
(bovine viral diarrhea virus, bovine respiratory syncytial virus, para-infulenza-3 virus, bovine 
herpes virus-1), and bacteria (Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, 
Mycoplasma bovis). Global economic impact of BRD is estimated to be >$3 billion/year(Watts 
and Sweeney, 2010). Antimicrobial administration is a mainstay of both prevention/control of 
disease and treatment of clinical disease. Table 1 contains a non-exhaustive list of antimicrobial 
products currently licensed in the United States (U.S.) for the treatment of BRD. Widespread 
bacterial pathogen resistance to antimicrobials commonly used for BRD is a very real concern 
shared by producers, practitioners, and the animal health industry. In the U.S. there are no routine 
surveillance programs to monitor antimicrobial resistance among BRD pathogens, however; 
independent and industry sponsored research can be found reporting surveillance-type data from 
different areas of the world.  
Observations from the medical field on antimicrobial resistance were first reported by medical 
practitioners as early as the late 1940s to early 1950s(Glisan et al., 1982). The first documented 
case of multiple drug resistance transfer by conjugation was reported in 1959 by Akiba and Ochiai 
in Japan(Watanabe, 1967). Specific to BRD, the first reports of multiple drug resistance in P. 
multocida and M. haemolytica (formerly Pasteurella haemolytica) were published by Chang and 
Carter in 1976(Chang and Carter, 1976).  
The first publications of research into the mechanisms of antimicrobial resistance are from the 
early 1960s. Similar publications specific for pathogens of BRD did not begin appearing in the 
literature until the early 1980s. Resistance genes have been found and described for the common 
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bacterial pathogens associated with BRD for the tetracyclines,(O'Connor et al., 2010, D'Amours 
et al., 2011, Kehrenberg et al., 2005, Klima et al., 2011, Singer et al., 1998, Michael et al., 2012b) 
fluoroquinolones,(Pardon et al., 2013, Michael et al., 2012b) beta-lactams,(Michael et al., 2012b, 
Klima et al., 2011, Alexander et al., 2013a) macrolides, (Desmolaize et al., 2011a, Desmolaize et 
al., 2011c, Kadlec et al., 2011, Klima et al., 2011, Michael et al., 2012b) sulfonamides,(Michael 
et al., 2012b) lincosamides,(Desmolaize et al., 2011c, Kadlec et al., 2011, Michael et al., 2012b) 
phenicols,(Katsuda et al., 2012, Kehrenberg et al., 2008, Michael et al., 2012b) and 
aminoglycosides(Michael et al., 2012b, Alexander et al., 2013a). 
Lubbers and Hanzlicek described the available literature on antimicrobial resistance by 
categorizing the information into two categories: 1) authors reporting the percentage of isolates 
that are susceptible or resistant, or 2) the minimal inhibitory concentration (MIC) distribution, i.e. 
the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism 
in an agar or broth dilution susceptibility test for either 50% (MIC50) or 90% (MIC90) of isolates 
tested(Lubbers and Hanzlicek, 2013). Also present in the literature are molecular investigations 
into the mechanisms of resistance from small pools of field isolates or specific strains known to 
carry single or multidrug-resistance.  
Studies reporting either an MIC distribution or a percentage of susceptible/resistant isolates often, 
but not always, provide a description of criteria used to determine isolate classification as 
susceptible, intermediate, or resistant. Comparison of results between publications is difficult, if 
not impossible, when these criteria are not described adequately. Even when described 
appropriately, differences in methodology may make comparison between datasets inappropriate.  
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Standardized antimicrobial susceptibility testing methods and interpretive criteria are described by 
the Clinical and Laboratory Standards Institute (CLSI) in document VET01-A4(Clinical and 
Laboratory Standards Institute VET01-A4, July 2013). The most recent listing of CLSI interpretive 
criteria are contained in the supplemental document VET01-S2(Clinical and Laboratory Standards 
Institute VET01-S2, July 2013). The Veterinary Antimicrobial Susceptibility Testing (VAST) 
subcommittee within the CLSI determines veterinary-specific interpretive criteria based on 
evaluating clinical isolates, wild-type isolate, and pharmacokinetic/pharmacodynamic cutoffs as 
described in CLSI document VET02-A3(Clinical and Laboratory Standards Institute and VET02-
A3, February 2008). 
The CLSI, in VET01-A4, defines Susceptible, Intermediate, and Resistant as follows: 
Susceptible – a category that implies that an infection due to the strain may be 
appropriately treated with the dosage regimen of an antimicrobial agent recommended for 
that type of infection and infection species, unless otherwise indicated; 
Intermediate – a category that implies that an infection due to the isolate may be 
appropriately treated in body sites where the drugs are physiologically concentrated or 
when a high dosage of drug can be used; also indicates a “buffer zone” that should prevent 
small, uncontrolled, technical factors from causing major discrepancies in interpretations; 
Resistant – resistant strains are not inhibited by the usually achievable concentration of 
the agent with normal dosage schedules and/or fall in the range where specific resistance 
mechanisms are likely (e.g., β-lactamase), and clinical outcome has not been predictable 
in effectiveness studies.  
 As outlined in Table 1, eleven antimicrobials have (non-generic) veterinary breakpoints 
established for the treatment of BRD as described in VET01-A4(Clinical and Laboratory 
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Standards Institute VET01-A4, July 2013). A CLSI-approved veterinary breakpoint applies to a 
specific combination of disease, pathogen, animal species, and antimicrobial treatment regimen. 
When one of these parameters is altered, implied clinical outcome as related to the breakpoint is 
no longer valid, and therefore, the predictive value of the breakpoint is suspect. Unfortunately, the 
literature contains a plethora of studies containing information based on non-standardized testing 
methods or interpretive criteria not validated for the condition being treated.(Apley, 2003) 
Applying CLSI interpretive criteria to data generated from susceptibility testing which did not 
adhere to CLSI standards is an example of inappropriate reporting. As such, all studies described 
herein have either used the criteria described by CLSI or have adequate reasoning for using 
different criteria.  
 Literature Review  
The scientific literature contained in PubMed, AGRICOLA, and CAB were searched in February 
of 2014 using the following combinations of terms: (((((((bovine respiratory disease) AND 
antibiotic resistance) OR antimicrobial resistance) AND Mannheimia haemolytica) OR 
Pasteurella haemolytica) OR Pasteurella multocida) OR Histophilus somni) OR Haemophilus 
somnus). Titles and abstracts were read and 105 articles that were relevant to the subject of BRD 
antibiotic resistance were attained for further review. Relevance, defined as an abstract stating an 
objective (or conclusion) related to an obvious attempt to characterize susceptibility or resistance 
of the three BRD pathogens within a population of cattle. Additionally, if the title was related to 
BRD and antimicrobial susceptibility or resistance and did not contain an abstract, the article was 
attained for review. 
 The first exclusion criteria involved removing publications not originating in North America or 
not in English. The next exclusion criterion applied was the removal of publications that did not 
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utilize CLSI (or the former title NCCLS) criteria. The final exclusion criterion was the removal of 
articles not focused on BRD in beef cattle. Ten articles investigating phenotypic resistance and six 
articles on genetic components involved in macrolide resistance in BRD bacterial pathogens are 
included in this review.  
 Reports of Phenotypic Resistance in North America 
Chang and Carter (1976) analyzed isolates of M. haemolytica (n=262) and P. multocida (n=141) 
from clinical cases of BRD sent to the Michigan State Laboratory during a three year period from 
1971 to 1974(Chang and Carter, 1976). Careful interpretation of these data must be used as the 
publication predates the establishment of CLSI interpretive criteria. However, this report was the 
first report of multi-drug resistant BRD bacterial pathogens in the scientific literature. They found 
that most of the isolates were resistant to at least one of the four antimicrobials tested 
(dihydrostreptomycin, tetracycline, penicillin, and chloramphenicol). Using susceptibility 
interpretive criteria described by Kirby and Bauer, they reported resistance to at least a single drug 
in 79.1% (148/187) and 96.1% (122/127) of P. multocida and M. haemolytica, respectively. This 
article is included as a historical reference, but the interpretive criteria differ from current criteria, 
and the methods pre-date CLSI standards, so comparison to susceptibility distributions using 
current standards would be inappropriate. 
In 1991, Post et al. published a report regarding the antimicrobial susceptibility patterns and MICs 
of P. multocida (n=158) and M. haemolytica (n=421) isolated from nasal swabs and tissue 
specimens submitted from cattle with BRD to the Texas Veterinary Medical Diagnostic 
Laboratory between February and June 1989(Post et al., 1991). The susceptible or resistant 
findings from this study are only marginally useful for comparison to current findings because of 
changes in CLSI interpretive criteria and uncertainty in comparing the plates used in this study and 
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the commercial plates currently used in microwell dilution testing. The M. haemolytica MIC50 and 
MIC90 values for ceftiofur were at or below 0.125 µg/ml, the lowest dilution tested. For 
tetracycline, the corresponding values for MIC50 and MIC90 were 2 and 16 µg/ml, respectively.   
Watts et al. published a survey of antimicrobial susceptibility findings involving a total of 888 
isolates recovered from BRD cases over a four year period from 1988-1992(Watts et al., 1994). 
The isolates (461 M. haemolytica, 318 P. multocida, and 109 H. somni) were sent from veterinary 
diagnostic laboratories to an Upjohn (Zoetis) laboratory for MIC determinations. Only isolates of 
M. haemolytica, P. multocida, and H. somni obtained from lungs of animals that had died from 
acute BRD were requested. No more than two isolates of each species from each herd (or feedlot) 
were received from the following states: Pennsylvania, Wyoming, Iowa, Washington, California, 
Missouri, Nebraska, Oregon, Kansas, Arizona, Texas, South Dakota, Montana, Minnesota, 
Oklahoma, Colorado, and Utah. The Canadian provinces of Saskatchewan, Alberta, and Quebec 
were included in year four. Minimum inhibitory concentrations using CLSI approved interpretive 
criteria were determined for the following antimicrobials: ceftiofur, tilmicosin (breakpoint not yet 
established at publication), and spectinomycin. The other antimicrobials were evaluated using 
CLSI interpretive criteria adapted from human medicine, not approved in relation to bovine 
respiratory disease. 
The cumulative results of this 4 year study are reported in Table 2. These MIC distributions 
represent the earliest published documentation of MIC distributions for major BRD pathogens 
using CLSI methods and microdilution methods consistent with current methods in diagnostic 
laboratories. The last two years of the studies utilized commercially available serial dilution 
microwell dilution plates. 
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The finding of significant resistance to tilmicosin in M. haemolytica and P. multocida using the 
breakpoints in the study led to the Watts et al. speculating on reasons for resistance to a new 
antimicrobial. Although the findings of tilmicosin resistance would have been dramatically 
decreased with the use of the subsequently approved breakpoints for M. haemolytica, their 
speculation of cross-resistance within the macrolide class of antimicrobials has since been 
substantiated(Kadlec et al., 2011, Van Donkersgoed et al., 2008, Desmolaize et al., 2011c). 
Welsh et al. monitored the trends in antimicrobial susceptibility on a total of 842 isolates over the 
span of 1994-2002 (Welsh et al., 2004). In total, they collected 390 M. haemolytica, 292 P. 
multocida, and 160 H. somni were isolated at the Oklahoma Animal Disease Diagnostic 
Laboratory from lungs from six to eighteen month-old beef cattle succumbed to pneumonia. They 
reported variable susceptibility to tetracycline (range 23-74%) and relatively stable susceptibility 
to both ceftiofur (96-100%) and enrofloxacin (89-98%) for M. haemolytica isolates over that time 
period. Pasteurella multocida susceptibility profiles remained constant for both ceftiofur (96-
100%) and enrofloxacin (96-100%) but a decline in florfenicol susceptibility from 100% to 86% 
was observed from when florfenicol first came to use in 1996 through 2002. As for H. somni, they 
found that susceptibility to commonly used antimicrobials remained consistently high (87-100). A 
summary of their observed data is reported for each pathogen across all years in Table 3. 
In a study on healthy feedlot cattle, Klima et al. isolated M. haemolytica from deep nasal swabs 
from a random selection of approximately 10% of animals from 30% of feedlot pens within two 
feedlots in southern Alberta, Canada during 2007 and 2008(Klima et al., 2014a). Swabs were taken 
from the same cattle on arrival and within 30 days of feedlot exit. Cattle were subjected to normal 
commercial practices; BRD cases were treated with either tulathromycin or ceftiofur. During the 
feeding period, in-feed ionophores (lasalocid or monensin) were administered, chlortetracycline 
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was fed at levels for liver abscess control, cattle deemed to be at high risk of BRD were 
administered pulse (1-6 g/hd per day) doses of chlortetracycline in the feed, and tylosin was fed in 
the diet for liver abscess control.  
Susceptibility testing by disk diffusion was performed on 409 M. haemolytica isolates collected 
during the Klima et al. study. Antimicrobial resistance was found to consistently be low. All 
isolates were found to be susceptible to ceftiofur, enrofloxacin, and florfenicol. Resistance was 
most common for oxytetracycline (n=16) and one isolate was found intermediate to tilmicosin. 
They reported no obvious trend in resistance among these isolates at entry or exit from either 
feedlot. Additionally, they found no trend correlating an isolates’ expression of resistance and the 
antimicrobial that was administered to their host. The authors used CLSI Interpretive breakpoints 
for applications other than bovine respiratory disease for amoxicillin/clavulanic acid, 
sulfamethoxazole/trimethoprim, ampicillin, gentamicin, and oxytetracycline.  
McClary et al. identified cattle that had received tilmicosin for treatment of BRD based on records 
of 16 randomized clinical trials conducted in confined cattle feeding facilities in seven different 
states from 1996-2004(McClary et al., 2011). The cattle in these studies had no previous history 
of antimicrobial usage (including metaphylaxis) and met the individual study definition for BRD. 
Isolates of M. haemolytica (n=878) and P. multocida (n=359) were collected via deep nasal swab 
prior to treatment with tilmicosin; calves yielding >1 pathogen were not included in the analysis. 
The minimum inhibitory concentration to tilmicosin was determined using CLSI standard 
methods. Only 0.8% of M. haemolytica and 6.9% of P. multocida pre-treatment isolates were 
phenotypically resistant to tilmicosin and most (73.7%) of the M. haemolytica isolates categorized 
as either not susceptible or resistant were obtained during two of the 16 clinical trials. Additionally, 
they found no associations between case outcome and the classification (susceptible or not 
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susceptible) of the isolate for either pathogen. The authors reported the case outcome data in 
figures only, with approximate clinical success rates for M. haemolytica of 62% for susceptible 
isolates (n = 688), 47% for intermediate susceptibility isolates (n = 57), and 38% for resistant 
isolates (n = 6). The P value for a difference in clinical success rate between susceptible isolates 
as compared to intermediate or resistant isolates was 0.08. The authors acknowledge the lack of 
power in the study due to the low number of resistant isolates. While the paper did not find a 
significant difference in clinical outcome between susceptible and resistant isolates, the low power 
of the paper does not allow the conclusion that there is no difference. 
In an attempt to find correlations of ante-mortem treatment regimens with post-mortem 
susceptibility patterns, Lamm et al. searched the Oklahoma Animal Disease Diagnostic Laboratory 
database for animals that died at the Oklahoma State University Willard Sparks Beef Research 
Center in 2007(Lamm et al., 2012).  Cattle were included in the analysis if they had died due to 
BRD, had chronicity of the lesions recorded, bacterial organisms were isolated, and susceptibility 
patterns of the bacterial organisms determined.  
The authors (Lamm et al.) reported highly variable susceptibility patterns to tilmicosin between 
M. haemolytica, P. multocida, and H. somni with 88% (15/17), 42% (6/14), and 0% (0/12) of those 
isolates, respectively, either being intermediate or resistant. When grouping all three pathogens 
together, only a small portion of the isolates were susceptible to tetracycline (17/42, 40%) but a 
large number of isolates were susceptible to enrofloxacin (42/43, 98%), ceftiofur (38/42, 90%), 
and florfenicol (31/43, 72%); the authors indicated that ceftiofur and enrofloxacin were 
administered to these cattle prior to death. Overall, they reported that their study showed 
susceptibility patterns of the bacterial organisms isolated from the lungs of feedlot cattle that died 
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with bronchopneumonia may not always relate to the antimicrobial treatments administered prior 
to death.  
A large investigation was undertaken by Portis et al. using isolates from pre- and post-mortem 
bovine specimens to detect changes of in vitro susceptibility of BRD clinical isolates from 2000 
to 2009(Portis et al., 2012). Isolates of M. haemolytica (n=2,977), P. multocida (n=3,291), and H. 
somni (n=1,844) from 24 diagnostic labs across the U.S. (isolates from 47 states) and Canada 
(isolates from 6 provinces) were included in the study. All isolates were from diseased or deceased 
animals without any knowledge of either the age or the previous antimicrobial treatments 
administered to the animals. All susceptibility testing was carried out in two Pfizer (Zoetis) 
laboratories using CLSI standardized testing methods and approved interpretive criteria. The 
testing panel consisted of ceftiofur, enrofloxacin, florfenicol, penicillin, tetracycline, and 
tilmicosin. Danofloxacin and tulathromycin were added to the panel in 2004. Individual MIC 
distributions are reported for each drug and year for M. haemolytica (n=2,977), P. multocida 
(n=3,291), and H. somni (n=1,844) in this report. The reader is referred to the original publication 
for review of the extensive tables.  
Among M. haemolytica isolates Portis et al. observed no apparent changes in MIC distributions 
for penicillin and ceftiofur. There was a decline in the percentage of isolates susceptible to 
danofloxacin over this study period. Declines in susceptibility, upward shifts in MIC distributions, 
and increases in MIC90 were reported for enrofloxacin, tilmicosin and tulathromycin. A marked 
decrease in isolate susceptibility to tilmicosin from 89.4% in 2000 to 59.5% in 2009 was observed. 
Additionally, a decrease in florfenicol susceptibility by 10% over the ten year period was observed. 
Approximately 50% of all M. haemolytica isolates demonstrated in vitro susceptibility to 
tetracycline over the ten year study period.  
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In this same study, isolates of P. multocida showed little or no change in MIC distributions, MIC50 
or MIC90 for both penicillin and ceftiofur.  Approximately 88% of isolates were susceptible to 
danofloxacin in 2004 and little change was observed over the five years it was included in the 
panel. There was an emergence of a few resistant isolates and a small increase in MIC90 for 
enrofloxacin. Tilmicosin displayed a shift towards a higher MIC distribution and the percentage 
of susceptible isolates decreased to 59.7% by the end of the study. No discernable trends up or 
down were observed for florfenicol or tetracycline. While a susceptibility of at least 90% was 
observed to tulathromycin, the MIC90 increased 3 fold over the 6 year period in which it was 
included in the panel.  
Trends in isolates of H. somni included more than 90% susceptibility to penicillin, a steady 
increase of MIC90 for danofloxacin, and a drop in susceptibility for enrofloxacin from 100% in 
2000 to 86% in 2009. Additionally, while the MIC50 remained constant, a decrease in florfenicol 
susceptibility and a shift towards higher MIC distributions was reported. The MIC50 of tetracycline 
increased multiple dilutions and therefore a decrease in tetracycline susceptibility was observed. 
A shift in MIC distributions for both tilmicosin and tulathromycin was reported.  
While commenting on trends across all three bacteria, Portis et al, reported that a majority of BRD 
isolates remained susceptible to danofloxacin, enrofloxacin, and florfenicol, but they did observe 
a slow increase in resistance to these drugs. All three pathogens remained 100% susceptible to 
ceftiofur throughout the ten year study period. Although there was substantial variation in levels 
of susceptibility to tetracycline, MIC distributions did not appear to change over the study period 
in this report. This report once again demonstrated a cross-resistance effect in the macrolide class 
of antimicrobials. In 2004, one year prior to the marketing of tulathromycin, a 2-6% resistance rate 
was noted across the three major BRD bacteria pathogens.  
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Using isolates from two previous studies(Klima et al., 2011, Alexander et al., 2013b) Alexander 
et al. evaluated tulathromycin resistance in M. haemolytica isolated from cattle with a known 
history of antimicrobial use over a three year period from four commercial feedlots in southern 
Alberta, Canada(Alexander et al., 2013a). This period started one year after approval of 
tulathromycin for treatment and prevention of bovine respiratory disease in Canada. 
Tulathromycin was approved in 2005 in the United States and in 2006 in Canada. As described 
above, deep nasal swabs were obtained from a random selection of 10% of animals from 30% of 
feedlot pens of healthy cattle upon arrival and again at ≥60 days on feed (DOF). All M. haemolytica 
isolates (n= 4,548 isolates from 796 of the 5814 cattle sampled) were initially screened for 
tulathromycin susceptibility by plating onto brain heart infusion plates supplemented with 2 µg/mL 
tulathromycin. Isolates that grew on these plates (n=5) were isolated from three calves and were 
subjected to PCR analysis for resistance genes. All five isolates contained aphA-1 and tet(H), 
conferring resistance to neomycin and oxytetracycline. Two isolates contained blaROB-1 encoding 
resistance to ampicillin and penicillin. However, none of the isolates contained the macrolide 
resistance genes screened for in this study, namely, erm(A), erm(B) , erm(F), erm(X), erm(42), 
msr(E)-mph(E). The three animals that harbored the resistant isolates received metaphylactic doses 
of tulathromycin and were isolated only at ≥60 DOF. However, in the opinion of those authors, 
the remarkably low rates of resistance in that study did not support any association between 
macrolide use and tulathromycin resistance. The current study showed that tulathromycin 
resistance from this population of feedlot cattle in western Canada was exceptionally low even 
after this antimicrobial had been used in Canada for a period of four years. In their opinion (Klima 
et al. and Alexander et al.), there was no evidence that the commercial practices used by the 
feedlots in this study selected for tulathromycin-resistant M. haemolytica.  
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Isolates from the Kansas State Veterinary Diagnostic Laboratory were used by Lubbers and 
Hanzlicek in determining the prevalence of multidrug-resistant M. haemolytica from BRD cases 
over the time period of 2009 to 2011(Lubbers and Hanzlicek, 2013). _ENREF_23Isolates (n=389) 
included in the analysis had to be bovine lung specimen culture positive for M. haemolytica from 
clinical cases (research cases excluded) that had susceptibility test results available. Citing a low 
rate of resistance to ceftiofur (n=2) the authors reported that no single isolate was resistant to all 
six drugs (ceftiofur, enrofloxacin, florfenicol, oxytetracycline, spectinomycin, and tilmicosin) 
analyzed in this study. Enrofloxacin and danofloxacin yielded equivalent results, so only 
enrofloxacin was included in the analysis. Tilmicosin and tulathromycin yielded the same 
susceptibility interpretation in 85.5% (153/179) of the isolates; of the remaining 26 isolates, 14 
were interpretation discrepancies of intermediate and susceptible, which had no effect on the 
resistant finding. Seven isolates were resistant to tulathromycin and intermediate or susceptible to 
tilmicosin; 5 isolates had the opposite relationship, displaying resistance to tilmicosin but 
susceptible or intermediate to tulathromycin.  
The prevalence of multidrug-resistance was alarming and increased over time in the Lubbers and 
Hanzlicek study. Using resistance to three or more antimicrobials as the definition for multidrug 
resistance, 42% (23/55), 46% (71/155), and 63% (113/179) of the isolates were classified as 
multidrug resistant in 2009, 2010, and 2011, respectively. By 2011, 25% of the isolates were 
resistant to 4 of 6 key antimicrobials (typically all but florfenicol and ceftiofur), and 35% were 
resistant to 5 of 6 key antimicrobials (all but ceftiofur). In this study, isolates found to be resistant 
to oxytetracycline were 3.52 times more likely (P=0.04) to be resistant to one or more additional 
antimicrobials compared to non-oxytetracycline-resistant isolates. Isolates resistant to tilmicosin 
were 2.64 times more likely (P=0.06) to be resistant to at least one other antimicrobial. There were 
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no statistically significant coresistance patterns for enrofloxacin, florfenicol, or spectinomycin 
over the three year period.  
Investigating the effects of subtherapeutic vs. therapeutic administration of macrolides on 
antimicrobial resistance in M. haemolytica, Zaheer et al. conducted a study on 40 eleven-month 
old beef steers in Alberta, Canada(Zaheer et al., 2013). All steers originated from the same ranch 
and had not received antimicrobials during their lifetime prior to inclusion in this study. Steers 
were housed in individual pens with 10 replicates per treatment (controls no antimicrobials, 
tilmicosin single subcutaneous injection, tulathromycin single subcutaneous injection, and tylosin 
phosphate at 11 ppm in the feed). Deep nasopharyngeal swabs were collected on arrival, prior to 
administration of antimicrobials and then weekly thereafter for the 28 day study period. Their data 
demonstrated that seven days post injection, M. haemolytica was detected in only one steer treated 
from the tulathromycin treatment group and none of the steers treated with tilmicosin, whereas 
60% of all steers were positive for this bacterium upon arrival (day 0).  This is suggestive that M. 
haemolytica were not macrolide resistant upon arrival and likely a reflection that these calves had 
no previous exposure to antimicrobials. In contrast to injectable macrolides, tylosin, in the feed, 
had no effect on the number of M. haemolytica in steers receiving this antimicrobial as compared 
to cattle that received no antimicrobials. M. haemolytica isolated from animals belonging to control 
and all three macrolide treatment groups throughout the study were found to be susceptible to all 
tested macrolides, an indication that both therapeutic and subtherapeutic administration did not 
contribute to macrolide resistance in M. haemolytica during the study. Isolates in the present study 
were also susceptible to all other antimicrobials.  
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 Genetic Components of Bovine Respiratory Disease Resistance 
While this review focuses on phenotypic characterization of antimicrobial resistance in bovine 
respiratory disease isolates, a selected review of genetic components helps in understanding the 
epidemiology of resistance spread. The understanding of macrolide resistance genetics in M. 
haemolytica and P. multocida were greatly advanced in a flurry of publications starting in 2011.   
In 2011, Desmolaize et al., reported on a novel rRNA methylase gene, erm(42), which had 
diverged from all previously characterized erm genes and therefore was previously undetected on 
PCR assays(Desmolaize et al., 2011b). Genetic analysis suggested acquisition from other members 
of the Pasteurellaceae and recent gene transfer among M. haemolytica and P. multocida.  
Soon thereafter, Kadlec et al., published a whole-genome sequencing evaluation of a 2005 
Nebraska P. multocida isolate which was resistant to tulathromycin(Kadlec et al., 2011). Prior to 
this analysis, multiple techniques had failed to determine the mechanism of resistance. Three new 
resistance genes were identified in this study: the rRNA methylase gene erm(42), the macrolide 
transporter gene msr(E), and the macrolide phosphotransferase gene mph(E).  
Desmolaize et al. demonstrated that these three genes are arranged in 3 distinct classes of resistance 
in M. haemolytica and P. multocida(Desmolaize et al., 2011c). The erm(42) gene alone confers 
resistance to macrolides, lincosamides, and streptogramin group B antimicrobials. The second 
class consists of a tandem arrangement of msr(E) and mph(E). The third class contains all 3 
resistance genes and displayed high resistance to all macrolides tested in this study (tulathromycin, 
gamithromycin, tilmicosin). 
Michael et al. characterized these genes within an integrative conjugative element (ICE) in an 
isolate of P. multocida that contained 12 antimicrobial resistance genes(Michael et al., 2012c). 
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This ICE, designated ICEPmu1, contains the resistance genes aadA25 
(streptomycin/spectinomycin), strA and strB (streptomycin), aadB (gentamicin), aphA1 
(kanamycin/neomycin), tetR-tet(H) (tetracycline), floR (chloramphenicol/ florfenicol), sul2 
(sulfonamides), erm(42) (tilmicosin/clindamycin), and msr(E)-mph(E) (tilmicosin/ 
tulathromycin). A complete blaOXA-2 (penicillins, first and second generation cephalosporins) was 
also identified but appeared to be nonfunctional in this isolate. The authors pointed to the 
sequences obtained as evidence suggesting that plasmids, gene cassettes, and insertion sequences 
have contributed to the development of the two resistance gene regions in this ICE.  The presence 
of these 12 resistance genes in a single ICE demonstrates the potential for transfer of multiple 
antimicrobial resistance genes in one horizontal gene transfer event.   
Michael et al. (Michael et al., 2012a) evaluated the same three genes in a recently published 
investigation of MICs of gamithromycin and tildipirosin using field isolates of M. haemolytica 
(n=29) and P. multocida (n=40) collected between 1999 and 2007(Van Donkersgoed et al., 2008). 
These isolates had previously been shown to carry the genes erm(42) and/or msr(E)-
mph(E)(Kadlec et al., 2011). If all three genes were present, the P. multocida isolates showed MICs 
of 16–64 µg/mL for gamithromycin and 16–32 µg/mL for tildipirosin, whereas similar MICs of 
32–64 µg/mL for both macrolides were seen for the corresponding M. haemolytica isolates. 
Ten P. multocida isolates that carried only erm(42) exhibited low MICs of 2–4 µg/mL for 
gamithromycin, but had higher MICs of 16–32 µg/mL for tildipirosin(Van Donkersgoed et al., 
2008). The single M. haemolytica that harbored only erm(42) showed MICs of 4 and 32 µg/mL 
for gamithromycin and tildipirosin, respectively. The two P. multocida isolates that carried only 
the msr(E)-mph(E) operon exhibited a high MIC of 32 µg/mL for gamithromycin and a low MIC 
of 2 µg/mL for tildipirosin. The genes erm(42) and msr(E)-mph(E) are part of the resistance gene 
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regions of the recently identified integrative and conjugative element ICEPmu1, which has been 
shown to move across genus boundaries and express its resistance genes in different hosts, such 
as P. multocida and M. haemolytica. Pronounced increases in the gamithromycin MICs were seen 
in the presence of msr(E)-mph(E), whereas distinct increases in the tildipirosin MICs were detected 
in the presence of erm(42). This report, yet again, demonstrates cross-resistance exists in the 
macrolide class of antimicrobials and is further evidence of BRD bacterial pathogens, due to cross-
resistance, exhibiting resistance to antimicrobials prior to them being available for use in the 
industry.  
The most recent evaluation of ICE-mediated antimicrobial resistance in BRD pathogens was 
published by Klima et al. in 2014, and documents the presence of ICE in M. haemolytica and H. 
somni isolated from U.S. feedlots(Klima et al., 2014b). Their investigation centered on 42 BRD 
mortalities in Alberta, Canada, 6 mortalities in Texas, and 20 mortalities in Nebraska. Isolates of 
M. haemolytica (55), P. multocida (8), and H. somni (10) were collected from lungs and nasal 
swabs. Forty-five percent (33/73) of all bacterial isolates displayed resistance to 3 or more 
antimicrobials. Thirty-three percent (18/55) of M. haemolytica isolates,37.5% (3/8) of P. 
multocida isolates, and 30% (3/10) of H. somni were resistant to more than seven antimicrobial 
classes, including aminoglycosides, penicillins, fluoroquinolones, lincosamides, macrolides, 
pleuromutilins, and tetracyclines. All of the multidrug-resistant isolates originated from the Texas 
and Nebraska feedlots. These isolates varied between 60% and 100% similarity based on PFGE 
analysis, which the authors point out indicates that resistance was not spread strictly by clonal 
dissemination.  
Eighteen of the M. haemolytica isolates, 3 of the P. multocida isolates, and 3 of the H. somni 
isolates contained ICE that conferred resistance for up to 7 antimicrobial classes. These ICE were 
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demonstrated to be transferred by conjugation from P. multocida to Escherichia coli and from M. 
haemolytica and H. somni to P. multocida.  
 Discussion 
Antimicrobial resistance among the bacterial pathogens commonly associated with BRD is well 
documented in the scientific literature and the occurrence of resistant isolates appears to be steadily 
increasing in reports with the ability to analyze temporal trends. Foreign researchers, although 
utilizing different industry wide production practices and drug prescription practices, cite the same 
concerns over increases and patterns in resistance in BRD pathogens, especially in concern to the 
fluoroquinolone class of antimicrobials(Kaspar, 2006, Katsuda et al., 2013, Pardon et al., 2013, 
Shin et al., 2005). Japanese researchers have observed resistance rates in fluoroquinolone 
antimicrobials to have increased up to four-fold from the period of 2006 to 2009(Katsuda et al., 
2013). 
In the United States, publications from diagnostic laboratory submissions(Lamm et al., 2012, 
Lubbers and Hanzlicek, 2013, Portis et al., 2012, Watts et al., 1994, Welsh et al., 2004, Chang and 
Carter, 1976) utilizing specimens from animals that likely died from un-responsive BRD report 
consistently higher rates of resistance as compared to those that report resistance rates of isolates 
from pre-treatment(McClary et al., 2011) or healthy cattle(Alexander et al., 2013a, Klima et al., 
2011, Zaheer et al., 2013). These contrasts fuel the controversy over whether diagnostic laboratory 
data are a valid means of monitoring antimicrobial resistance trends due to the biased nature of 
diagnostic laboratory submissions. Unless the bias towards challenging cases with high morbidity 
and/or case fatality has dramatically changed, then trends in diagnostic laboratory data suggest that 
the pathogens involved in non-responsive and high-morbidity BRD challenges are displaying an 
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increasing incidence of resistance to many of the antimicrobials used in control and therapy of this 
disease.  
Studies which point to limited or non-existent resistance prevalence in small, confined populations 
exposed to antimicrobials do little to inform the discussion concerning the potential for 
antimicrobial use to enable spread of resistance through plasmids, integrative conjugative elements 
(ICE), or clonal spread.  Exposure of a population to antimicrobials in the absence of an existing 
resistant pathogen population relies on de-novo mutations for resistance and then selection for the 
isolates with these genetic characteristics or phenotypic expression of quiescent genes already 
present. The fact that many of the isolates discussed in this review contain multiple resistance 
genes grouped together on some type of transferrable element argues against the concept of de-
novo mutation in individual animals or small populations, and instead supports the hypothesis that 
much of our challenge in resistant BRD pathogens stems from selection for existing multi-drug 
resistant mobile genetic elements or the resistant pathogens which bear them.  
The characterization of these pathogen isolates related to the combination of antimicrobial 
resistance, virulence, and dominance in colonization remains to be established. It is reasonable to 
hypothesize that pathogens which contain this “trifecta” would be an enormous challenge within 
existing beef production systems. The data reviewed in this paper suggest that extensive 
investigations are needed on where selection pressure is being applied for organisms with 
resistance phenotypes encoded for by mechanisms such as an ICE. The design of these 
investigations will be informed by findings of recent and ongoing studies evaluating the 
epidemiology of BRD pathogens, including investigations of Mannheimia haemolytica population 
distributions within individual animals and across cattle populations. 
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 Conclusion 
Due to the disparate data from the few studies that investigate susceptibility testing of BRD 
pathogens, it is difficult, if not impossible to perform a quantitative assessment or meta-analysis 
of the studies presented in this review. Even though diagnostic lab data is heavily criticized by 
some, it is difficult to argue against the appearance of a trend in these data. Following these reports 
chronologically shows an apparent trend of a decrease in susceptibility of the three major BRD 
pathogens to most of the antimicrobials commonly used for treatment and control of BRD. It is 
possible that the cattle in diagnostic studies represent a specific niche in the population that has a 
preponderance for harboring resistant pathogens and this needs further investigation. However, the 
fact that there are isolates within the population that phenotypically express high levels of pan-
resistance to the antimicrobials used both in treatment and control might suggest that it is unwise 
to use the same antimicrobials for both treatment and control.  
An additional point to consider is the previous lack in technology allowing for the detection of the 
presence of genetic resistance. Most studies in this review focus on culture and sensitivity which 
are essentially testing phenotypic expression without any knowledge of the genotype. Perhaps, the 
“healthy cattle” that display lower levels of resistance have not been exposed to the selection 
pressure through disease and subsequent treatment, to necessitate the phenotypic expression of 
resistance genes currently present in their genome as ICE elements or other stand-alone resistance 
mechanisms? Owing to the relatively recent advances in technology allowing rapid and 
economically efficient genetic sequencing methods, our research group is currently investigating 
this in further detail. 
This review highlights the continued importance of judicious use of antimicrobials in all sectors 
veterinary medicine to ensure antimicrobials will remain effective into the future. 
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 Figures and Tables 
 
Trade Name Generic Drug Name Product Class Approval Year 
CLSI 
Approved 
Breakpoint 
LA-200 
Oxytetracycline 200 
mg/ml 
Tetracycline 1980 Yes* 
Dual-Pen Penicillin β-Lactam 1984 Yes* 
Tylan Tylosin Macrolide 1985 - 
Polyflex Ampicillin trihydrate β-Lactam 1985 - 
Micotil Tilmicosin Macrolide 1992 Yes 
Nuflor Florfenicol Amphenicol 1996 Yes 
Naxcel Ceftiofur sodium β-Lactam 1998 Yes 
AdSpec Spectinomycin Aminocyclitol 1998 Yes 
Baytril 100 Enrofloxacin Fluoroquinolone 1998 Yes 
Excede 
Ceftiofur crystalline free 
acid 
β-Lactam 2003 Yes 
Tetradure 
Oxytetracycline 300 
mg/ml 
Tetracycline 2003 Yes* 
Draxxin Tulathromycin Macrolide 2005 Yes 
Excenel Ceftiofur hydrochloride β-Lactam 2008 Yes 
Advocin  Danofloxacin Fluoroquinolone 2002 Yes 
Zactran Gamithromycin Macrolide 2011 Yes 
Zuprevo Tildipirosin Macrolide 2012 Yes 
Table 2.1– Non-exhaustive list of antimicrobial products licensed in the United States for treatment 
and/or prevention/control of Bovine Respiratory Disease. *Generic label breakpoints established 
using field wild-type isolates, in vitro pharmacokinetic, and pharmacodynamic data in the absence 
of randomized clinical field trials with treatment outcomes 
  
49 
Mannheimia haemolytica susceptibility determined by Kirby-Bauer disc diffusion (%) 
  1994 1995 1996 1997 1998 1999 2000 2001 2002 
Ceftiofur 97 98 100 100 98 100 98 96 97 
Enrofloxacin - - - - - 96 98 89 98 
Florfenicol - - 100 96 98 97 96 87 90* 
Spectinomycin 65 49 71 53 55 63 45 29 51* 
Tilmicosin 90 78 93 83 80 74 85 71 79* 
  
Ampicillin 42 64 82 81 63 76 76 57 58 
Cephalothin - - - - - - 98 96 97 
Erythromycin 90 91 39 84 69 77 67 38 18* 
Sulfachloropyridizine 92 - 93 94 88 93 87 90 - 
Tetracycline 23 46 74 58 42 63 44 34 54 
SMX/TMP 99 90 98 94 95 93 94 94 96 
                    
Pasteurella multocida susceptibility determined by Kirby-Bauer disc diffusion (%) 
  1994 1995 1996 1997 1998 1999 2000 2001 2002 
Ceftiofur 98 100 100 100 97 100 99 96 100 
Enrofloxacin - - - - - 96 97 96 100 
Florfenicol - - 100 100 100 97 86 88 96* 
Spectinomycin 34 63 33 63 46 63 31 42 47* 
  
Ampicillin 83 96 100 100 95 76 96 93 98 
Cephalothin - - - - - - 96 100 100 
Erythromycin 93 89 90 89 79 77 51 41 34* 
Sulfachloropyridizine 43 - 65 62 57 93 29 50* - 
Tetracycline 71 58 52 53 56 63 40 44 58* 
Tilmicosin 92 81 76 82 84 76 60 58 73* 
SMX/TMP 100 88 95 94 95 93 85 76 89* 
                    
Histophilus somni susceptibility determined by Kirby-Bauer disc diffusion (%) 
  1994 1995 1996 1997 1998 1999 2000 2001 2002 
Ceftiofur 100 100 88 100 100 89 100 97 100 
Enrofloxacin - - - - - 100 100 100 100 
Florfenicol - - 100 100 100 100 96 100 100 
Spectinomycin 65 70 81 83 74 78 73 86 71 
  
Ampicillin 96 100 94 100 95 89 100 97 100 
Cephalothin - - - - - - 100 97 100 
Erythromycin 100 100 94 94 95 100 96 97 96 
Sulfachloropyridizine 68 - 69 76 78 59 85 86 - 
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Tetracycline 88 100 94 100 94 100 96 100 100 
Tilmicosin - 88 87 94 87 93 88 97 96 
SMX/TMP 96 100 94 100 100 94 100 100 100 
*indicates significant decline (P < 0.05) 
CLSI approved interpretive criteria related to bovine respiratory disease and this pathogen for these 
antimicrobials  
Table 2.2 – Summary of susceptibly data of Mannheimia haemolytica, Pasteurella multocida, and 
Histophilus somni isolated from lungs of bovine respiratory disease cases submitted to the Oklahoma Animal 
and Disease Diagnostic Laboratory between 1994 and 2002. (Welsh et al.) Note: Tilmicosin has CLSI 
approved interpretive criteria only for Mannheimia haemolytica in BRD 
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Chapter 3 - Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary 
epithelial lining fluid in naturally occurring bovine respiratory disease in multi-source 
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 Abbreviations used: 
BRD – bovine respiratory disease 
PELF – pulmonary epithelial lining fluid 
PK – pharmacokinetics  
PD – pharmacodynamics 
MM – mass medication 
CON – control 
NPS – deep nasopharyngeal swab 
BAL – bronchoalveolar lavage fluid 
Cl – clearance 
V – volume of distribution 
NCA – noncompartmental analysis 
AUC24 – area under the curve from time 0 to 24 hours 
AUC∞ - area under the curve extrapolated to infinity 
AUC0-t – area under the curve from time 0 to the time at which the last sample was collected  
CMAX – maximum concentration 
Kel – elimination rate constant 
MIC – minimum inhibitory concentration 
MRT – mean residence time 
SC – subcutaneous  
KSVDL – Kansas State Veterinary Diagnostic Laboratory 
USMARC – United States Meat Animal Research Center 
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 ABSTRACT 
The objectives of this study were to determine if 1) an association exists between individual 
pharmacokinetic parameters and treatment outcome when feeder cattle were diagnosed with 
bovine respiratory disease (BRD) and treated with gamithromycin (Zactran®) at the label dose and 
2) if there was a stronger association between treatment outcome and gamithromycin concentration 
in plasma or in the pulmonary epithelial lining fluid (PELF) effect compartment. The study design 
was a prospective, blinded, randomized clinical trial utilizing three groups of 60 (362-592 lb) 
steers/bulls randomly allocated within origin to sham injection or gamithromycin mass medication. 
Cattle were evaluated daily for signs of BRD by a veterinarian blinded to treatment. Animals 
meeting the BRD case definition were enrolled and allocated to a sample collection scheme 
consisting of samples for bacterial isolation (bronchoalveolar lavage fluid and nasopharyngeal 
swabs) and gamithromycin concentration determination (PELF and plasma). 
Gamithromycin susceptibility of M haemolytica (n=287) and P multocida (n=257) were 
determined using broth microdilution with frozen panels containing gamithromycin at 
concentrations from 0.03 to 16 µg/mL.  A two compartment plasma pharmacokinetic model with 
an additional compartment for gamithromycin in PELF was developed using rich datasets from 
published and unpublished studies. The sparse data from our study were then fit to this model 
using nonlinear mixed effects modeling to estimate individual parameter values. The resulting 
parameter estimates were used to simulate full time-concentration profiles for each animal in the 
current study. These profiles were analyzed using non-compartmental methods so that PK/PD 
indices (AUC24/MIC, AUC∞/MIC, CMAX/MIC) could be calculated for plasma and PELF (also 
T>MIC) for each individual. 
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The calculated PK/PD indices were indicative that for both M haemolytica and P multocida a 
higher drug exposure in terms of concentration, and duration of exposure relative to the MIC of 
the target pathogen was favorable to a successful case outcome. A significant association was 
found between treatment success and PELF AUC0-24/MIC for P multocida. The calves in this study 
demonstrated an increased clearance and volume of distribution in plasma as compared to the 
healthy calves in two previously published reports. Ultimately, the findings from this study 
indicate that higher PK/PD indices were predictive of positive treatment outcomes. 
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 INTRODUCTION 
Gamithromycin (ZACTRAN®, Merial Animal Health, Duluth, GA, USA), a macrolide of 
the azalide subclass, is approved for both treatment of BRD caused by Mannheimia haemolytica, 
Pasteurella multocida, Histophilus somni, and Mycoplasma bovis and the control of BRD caused 
by M haemolytica and P multocida (Merial, 2011). Macrolide antibiotics, in general, are 
bacteriostatic through inhibition of bacterial RNA-dependent protein biosynthesis (Jain & 
Danziger, 2004). However, gamithromycin can also be bactericidal with minimum bactericidal 
concentrations only 1 dilution higher than the respective MIC (Huang, Letendre et al., 2010). The 
tendency for macrolides, especially azalides, to accumulate in inflamed tissue has been described 
previously (Amsden, 2001). This fact coupled with the known extensive tissue distribution of 
macrolides, has sparked interest in the veterinary literature concerning the exposure response 
relationship at the site of action as it pertains to the newer long-acting injectable macrolide 
formulations (Nowakowski, Inskeep et al., 2004; Womble, Giguere et al., 2006; Venner, Peters et 
al., 2010; Menge, Rose et al., 2012; Villarino, Brown et al., 2013; Villarino, Lesman et al., 2013; 
Villarino, Brown et al., 2014). 
Recent work examining the concentrations of antibiotics in PELF of healthy animals has 
been performed to describe the disposition of gamithromycin in beef calves (Giguere, Huang et 
al., 2011). Giguere et al. found that gamithromycin was rapidly absorbed and reached potentially 
therapeutic concentrations in PELF within 30 minutes after SC administration. To the authors’ 
knowledge all previous work describing the distribution of these drugs in cattle has been done in 
healthy subjects and there are no publications describing the PK and PD of a macrolide class 
antibiotic in the PELF under the conditions of naturally occurring BRD. To that end, the objectives 
of this study were to: 1) develop a compartmental PK model based upon existing PK data, 2) use 
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sparse data collected in the present study to estimate parameter values for the animals in this study 
population, 3) use the model estimated parameters to simulate complete concentration-time 
profiles of gamithromycin in the central and PELF effect compartments of each animal, 4) 
determine if a relationship exists between plasma and/or PELF concentrations and treatment 
outcome, and finally 5) determine the PK/PD indices associated with treatment success in naturally 
occurring BRD. 
 
 MATERIALS AND M ETHODS 
 Animals and husbandry 
One hundred and eighty cattle judged to be at high risk for BRD (overall average body 
weight of 470 pounds (362-592 lbs)) were sourced from Athens, Tennessee (n=60), Richmond, 
Kentucky (n=60), and Maryville, Missouri (n=60) as part of another study. Commingled steers 
and bulls of multiple origins and mixed breeds were acquired at each sale barn and transported to 
a small research feeding facility in Kansas where they were housed in open air, dirt floor group 
housing pens for the duration of the trial. 
 
 Study design and treatment allocation 
The study design was a prospective, blinded, randomized clinical trial with masked 
subjective evaluators and was approved by the Kansas State University Institutional Animal Care 
and Use Committee.  
Cattle were randomized to one of two treatments prior to arrival (by ear tag ID administered 
at the sale barn) so that each load was randomly allocated into two pens per source, one for each 
treatment (6 total pens in the study, 3 for each treatment). At initial processing, cattle assigned to 
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treatment 1 served as untreated controls (CON) receiving saline at 2 mL/110 pounds 
subcutaneously in the neck; while cattle randomly allocated to treatment 2 received treatment 
(MM) for the control of BRD with gamithromycin at the label dose of 6 mg/kg (2 mL/110 lb) 
subcutaneously in the neck.  Additionally, all cattle received a modified live viral respiratory 
vaccine, clostridia vaccine, growth implant, injectable anthelminthic, duplicate tags for study 
identification, and were examined to ensure that no clinical signs of BRD were present on arrival. 
Once in their pens, cattle were fed a ration according to practices typical of the feedlot industry.  
 
 Clinical scoring and disease diagnosis 
Daily pen observations were performed by a veterinarian masked to treatment allocation. 
Clinical scoring was by exclusion, i.e. only cattle scoring 1-4, as described in Table 1, were 
recorded on daily observation forms and brought to the chute for further evaluation. Cattle having 
a rectal temperature of ≥104.0˚F (≥40.0˚C) and a clinical score of ≥1 were diagnosed with BRD 
and included in this study. Cattle with a clinical score of ≥1 but not meeting the temperature 
requirements were returned to their home pen without treatment for further observation. Animals 
were clinically scored each day but were not eligible for treatment of BRD until the post-control 
treatment moratorium had elapsed. Control animals were immediately eligible for treatment of 
BRD and those receiving mass medication were eligible for treatment on study day 8 (7 day 
moratorium).  
 
 Sampling allocation and collection procedures 
The day of enrollment (first diagnosis of BRD) was designated as Day 0 for each calf. 
Cattle meeting inclusion criteria for the study were randomly allocated to a sample collection 
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scheme consisting of collection of NPS, BAL, and plasma (Table 2). Allocation to sample 
collection procedures were performed in advance, in blocks of three, to ensure that there was an 
equal distribution across sampling time points in order to account for the fact that actual number 
of cases of naturally occurring BRD was unknown beforehand. Samples collected on Day 0 were 
collected just prior to treatment with gamithromycin. All treatments and procedures at the chute 
were performed by trained personnel not involved in clinical scoring of cattle. The veterinarian 
responsible for clinical scoring was not present for treatments and procedures performed at the 
chute and therefore remained masked throughout the duration of the study period. Deep 
nasopharyngeal swabs and an aliquot of BAL fluid were immediately sent for bacterial culture 
while samples of plasma and BAL fluid were processed and frozen at < -70˚C for later analysis by 
HPLC-MS/MS. 
The BAL procedure was used to collect PELF fluid from manually restrained, non-sedate 
cattle. The BAL tube (Bivonna, BAL-240) was introduced into the trachea via the nasal passage 
and advanced until wedged into a deep bronchus. Sterile saline (240 mL) was infused in 60 mL 
aliquots and aspirated immediately after each aliquot. Recovered BAL fluid was collected into a 
250 mL centrifuge tube, mixed well, divided evenly among four 50 mL centrifuge tubes, then 
placed on ice and centrifuged in the feedlot laboratory within 40 minutes of collection.  One 
randomly selected cell pellet was resuspended in liquid Amies media and submitted to the KSVDL 
for bacterial isolation. The BAL tubes were cleaned by plasma sterilization between collection 
procedures to prevent cross contamination.  
Deep nasopharyngeal swabs were collected from both nares by a veterinarian trained in the 
procedure. Briefly, a double guarded sterile uterine swab was introduced through the nares into 
the nasal cavity and guided to the point where resistance was met in the area of the nasopharyngeal 
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tonsilar tissue. At this point the double guarded swab was retracted slightly, the interior sleeve 
portion containing the swab was pushed through the exterior guard, and the swab advanced from 
the sleeve and rotated to ensure a sufficient sample of the mucous and tonsilar secretions from the 
pharyngeal tissues. The swab was retracted into the guarded sleeve to prevent contamination while 
exiting the nares. The swabs were placed in liquid Amies media and transported on ice to the 
KSVDL for bacterial culture and isolation.  
Blood was collected into 10 mL sodium heparin vacutainer tubes via jugular venipuncture 
and tubes were centrifuged in the feedlot laboratory at 500 X g for 15 minutes. Plasma was pipetted 
into duplicate cryovials and stored along with other cryovial samples of BAL fluid (duplicates of 
PELF fluid, resuspended cell pellets, and urea analysis samples from both PELF and plasma) at < 
-70˚C until analysis. 
 
 Treatment administration and case outcome determination 
Cattle diagnosed with BRD were randomly assigned to a sample collection scheme, treated 
with gamithromycin according to label directions (6 mg/kg) SC in the neck, and returned to the 
home pen. Case outcome was determined until Day 9, post treatment. A treatment failure was 
defined as the calf meeting study inclusion criteria as previously described, if the calf was a clinical 
score 3 regardless of rectal temperature, or if a calf died from BRD. Those cattle not categorized 
as a treatment failure by Day 9 were therefore considered treatment successes. Therefore, 
comparisons within this manuscript are between cattle deemed a treatment success versus those 
that were deemed a treatment failure. 
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 Gamithromycin concentration analysis 
Concentrations of gamithromycin in PELF and plasma were determined by Merial 
personnel masked to treatment. Samples were analyzed by reversed-phase HPLC with detection 
via MS/MS transitions by methods previously described (Giguere, Huang et al., 2011). The limit 
of detection and limit of quantitation were 5 ng/mL and 10 ng/mL, respectively. The concentration 
of gamithromycin in PELF was estimated using the ratio of urea in BAL fluid to that as measured 
in serum as described previously (Rennard, Basset et al., 1986). 
 
 Bacterial isolation and MIC determination  
Nasopharyngeal swabs and PELF samples were plated directly onto trypticase soy + 5% 
blood, chocolate, and MacConkey agar plates and incubated in 5% CO2 at 37˚C for 18-24 hours. 
Up to 12 colonies displaying growth characteristics typical of M haemolytica and P multocida 
were isolated in pure culture. Identity was confirmed using MALDI-TOF® (Bruker Daltonics, 
Billerica, MA, USA) and frozen for later susceptibility testing at the USMARC in Clay Center, 
Nebraska. 
Gamithromycin susceptibility of M haemolytica and P multocida isolates were performed 
at USMARC by broth microdilution with frozen panels from TREK Diagnostic Systems® 
(Thermo-Fisher Scientific Inc., Waltham, MA, USA) containing gamithromycin at concentrations 
ranging from 0.03 to 16 µg/mL. Bacterial suspensions were prepared and susceptibility plates 
inoculated as per CLSI guidelines (Clinical and Laboratory Standards Institute & VET01-A4, July 
2013). In brief, isolates were cultured on chocolate agar and incubated with increased CO2 at 37˚C 
for 18-20 hours. Bacterial suspensions equivalent to 0.5 McFarland standard were made by 
suspending 3 to 5 isolated colonies from each plate, into 5 mL of demineralized water. Mueller-
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Hinton broth tubes were then inoculated with 140 µl of the resulting bacterial suspensions. A 12 
channel pipette was used to dispense 50 µl of this suspension into each of 12 wells in the panel, 
such that each panel could be used to evaluate the susceptibility of 8 strains. Plates were sealed 
and incubated at 37˚C for 18-20 hours at which time the plates were visually inspected and MIC 
values determined by noting the lowest concentration of antibiotic that completely inhibited 
growth. Determination of susceptible, intermediate or resistant were based off of clinical 
breakpoints established for gamithromycin by CLSI (Clinical and Laboratory Standards Institute 
& VET01-A4, July 2013). 
 
 Pharmacokinetic modeling and pharmacodynamics 
A user defined, two compartment plus PELF compartment was built in Phoenix NLME® 
(Certara L.P., Cary, NC, USA). The model schematic can be seen in Figure 1. The differential 
equation describing this model is as follows:  
𝑑𝐴1
𝑑𝑡
= −(𝐴1 ∗ 𝑘10) + (𝐴𝑎 ∗ 𝑘𝑎) − (𝐴1 ∗ 𝑘12 − 𝐴2 ∗ 𝑘21) − (𝐴1 ∗ 𝑘13 − 𝐴𝑝𝑒𝑙𝑓 ∗ 𝑘31) 
𝑑𝐴2
𝑑𝑡
= (𝐴1 ∗ 𝑘12 − 𝐴2 ∗ 𝑘21) 
𝑑𝐴𝑝𝑒𝑙𝑓
𝑑𝑡
= (𝐴1 ∗ 𝑘13 − 𝐴𝑝𝑒𝑙𝑓 ∗ 𝑘31) 
where A1 is the amount in central compartment, k10 is the elimination rate constant from the central 
compartment, Aa is the amount at the site of the SC injection, Ka is the absorption rate constant 
from the site of the injection, k12 is the rate constant for the central to the peripheral compartment, 
A2 is the amount in the peripheral compartment,  k21 is the rate constant for the peripheral to the 
central compartment, k13 is the rate constant for the central to the PELF compartment, Apelf is the 
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amount in the PELF compartment, and k31 is the rate constant for the PELF to the central 
compartment.  
Data collected from published (Huang, Letendre et al., 2010; Giguere, Huang et al., 2011) 
and unpublished (personal communication with coauthor RKT) PK trials of gamithromycin in 
cattle were used to generate initial estimates to develop the model. These data consisted of samples 
of plasma and PELF concentrations after administration of the label dosage of gamithromycin in 
healthy beef calves. When specific data were not available in the manuscript, data was extracted 
using an online tool, WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/).   
Next, the sparse data from this trial were integrated into the model using a non-linear mixed 
effect approach, without the inclusion of covariates, to predict parameter values for each animal 
in our study. Parameter values were calculated for each individual animal within this study by use 
of the typical value and the individual ETA (e.g. V = tvV * exp(nV)). Individual ETA values for 
each parameter of the PK model can be found online in supplemental materials. One hundred 
simulations were conducted predicting complete plasma and PELF time concentration curves for 
each animal in this current study. Average simulated data were analyzed by NCA  in order to 
compare the results of this study to those in the literature and to calculate PK/PD indices for plasma 
(AUC24/MIC, AUC∞/MIC, CMAX/MIC) and PELF (AUC24/MIC, AUC∞/MIC, CMAX/MIC, 
T>MIC). Clearance and V were calculated from extrapolated graphical data contained in each 
manuscript as follows and for the calves in this study; Cl = Dose/AUCinf and V = Cl/Kel. 
The PK/PD indices were calculated from AUC24, AUC∞, and CMAX of the simulated plasma 
and PELF time-concentration profiles of each individual animal and the MIC of the sample 
collected from that animal. T>MIC was calculated using predicted PELF data only because plasma 
concentrations did not reach levels above the MICs in this study. The MIC used for the calculation 
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was from the isolate with the highest MIC collected from that calf at time 0 only (i.e., prior to 
therapeutic treatment) but could be from either BAL or NPS. Time above MIC was not calculated 
for plasma as the plasma concentrations did not reach that of the lowest MIC dilution tested.  
 
 Statistical analysis  
A generalized linear mixed model fit by maximum likelihood regression was built in 
STATA (Stata/SE 12.1 for Windows, StataCorp LP, College Station, TX, USA) to compare 
morbidity between MM and CON using pen as a random clustering effect. Initial covariates 
included in the model, but ultimately excluded due to lack of significance, were trailer 
compartment and state of animal origination.  
Statistical comparisons of PK and PD parameters between treatment outcome (success and 
failure) were performed with the Kruskal-Wallis test for nonparametric data using SAS® software 
(Version 9.3, SAS Institute Inc., Cary, NC, USA). The level of significance was set at P ≤ 0.05 
using a two-tailed test. Both compartmental and NCA PK parameters were compared statistically 
since this report focuses on both types of modeling. 
 
 RESULTS 
 Morbidity outcome 
Descriptive morbidity, mortality, and treatment failure data can be found in Table 3. 
Treatment for control of BRD with gamithromycin resulted in a numerically lower morbidity but 
a numerically higher relapse rate (therapeutic failure), however, these differences were not 
statistically significant (P = 0.25). Total morbidity throughout the 28 days of the trial was much 
lower than anticipated and the power of the study may therefore have been insufficient to detect 
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significant differences in morbidity between sham injected cattle and those treated for control of 
BRD with gamithromycin. 
 
 PK model development   
Model development was guided by goodness of fit plots within the modeling software. The 
results of the final model can be seen in Figure 2. There is an excellent fit of predicted data to 
actual data in plasma and PELF at lower concentrations. The model slightly under-predicts PELF 
at higher concentrations but this is likely due to difficulty in accurately predicting the Ka due to 
the paucity of data in this area of the curve. 
 
 Pharmacokinetics of study animals 
The estimated typical value of the compartmental model parameters for the population 
(regardless of treatment outcome) are summarized in Table 4. Note that the volume parameters (V 
and VPELF) are not weight normalized because weight was not a significant covariate in the 
nonlinear mixed effects model.  
The simulated full time concentration curves for the treatment successes and failures can 
be found in Figure 3. The Cl, V, rate constants, CMAX, AUC0-t, AUC24, AUC0-∞, and MRT 
calculated from these curves were compared between treatment successes and treatment failures 
and no statistical differences were observed. CMAX was, however, numerically higher in the 
treatment success group.  Variability was high and this may or may not be a true difference (plasma 
P=0.12, PELF P=0.22). 
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 MIC and pharmacodynamics 
The MIC distribution for the clinical (BAL and NPS) isolates of M haemolytica (n=287) 
and P multocida (n=257) from this trial can be seen in Figure 4. Isolates of M haemolytica in the 
susceptible category represent 60% of the isolate population and those in the resistant category 
encompass 36% as compared to 31% and 68% for P multocida, respectively. The isolates tested 
were collected over all time points (0, 12, 24, and 120 hours post treatment) from both CON and 
MM cattle and therefore represent isolates not yet exposed to therapeutic drug as well as isolates 
exposed to gamithromycin in the later sample collections. Additionally, nine of the 26 cattle 
diagnosed with BRD and subsequently sampled were from the treatment group receiving mass 
medication with gamithromycin on arrival and would have therefore, had previous exposure to 
gamithromycin. 
The bivariate histogram in Figure 5 shows the MIC distribution for both M haemolytica 
and P multocida at time 0 by treatment outcome. This graphic suggests that the sample size was 
not equivalent across outcome groups, but the MIC comparisons within outcome group are quite 
similar. As such, there were just 22 cattle in the success group and 4 in the failure group with the 
plots representing a single isolate per calf for those yielding an isolate (4 calves did not yield an 
isolate at time 0).  Due to small sample size and confounding of arrival treatment (CON and MM) 
within therapeutic treatment outcome it was not possible to statistically compare the MIC by 
outcome. However, it can be visually appreciated that there is a symmetry in each group with the 
treatment success group having 10 susceptible isolates and 8 resistant isolates. The treatment 
failures represent cattle yielding 2 susceptible and 2 resistant isolates, prior to treatment. 
The results of the PK/PD index calculations can be found in Table 5 and represent a 
comparison between treatment successes and failures by pathogen. Although the standard error in 
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the failure group is relatively large and likely reflective of the small sample size, comparing the 
means between outcomes indicate that in all cases, more active ingredient is present and for a 
longer duration in the treatment success group. Statistical differences between treatment successes 
and failures were noted in AUC24/MIC (P = 0.04) for P multocida in PELF. Additionally, an 
association (P = 0.10) was observed with higher AUC24/MIC, AUC∞/MIC, and CMAX/MIC for 
treatment successes as compared to failures in plasma, and AUC24/MIC (P = 0.07) in PELF for M 
haemolytica. Half of the failures (2/4) and 41% (7/17) of the cattle in the success group were from 
the MM group that received gamithromycin on arrival to the feedyard. Those cattle from the MM 
group accounted for 80% (8/10) of the isolates displaying an MIC of ≥16 µg/mL (at time 0). The 
isolate yielding the highest MIC, as cultured prior to treatment for BRD, is reported by treatment 
group (CON, MM) in Table 6. 
Comparison of the PK parameters resulting from this study compared to those of previously 
published studies can be found in Table 7. The calves in this study demonstrated an increased Cl 
and V in plasma as compared to the healthy calves in the two previous reports. The MRT of both 
plasma and PELF are quite similar to those reported previously by Giguere et al. Both the CMAX 
and AUC0-∞ reported herein, are quite different, especially in plasma, from the previously 
published reports of gamithromycin PK in healthy cattle (Huang, Letendre et al. 2010; Giguere, 
Huang et al. 2011). 
 
 DISCUSSION 
Trials involving sparsely sampled data, such as this one, represent difficulties in parameter 
estimation. Mixed effects models help to overcome these challenges by partitioning sources of 
variability in hierarchical statistical models, there-by allowing a reduction in the variance of the 
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estimated population parameters. These models also have the advantage of allowing quality 
analysis from fewer samples, thereby sparing expense and the stress from additional animal 
handling. However, quality prior information on the parameters is a requirement to inform these 
models (Dodds, Hooker et al., 2005; Riviere, 2011; Mould & Upton, 2012). It was fortunate to 
have had access to rich data to externally validate the model. This allowed a comparison of the 
simulated data in this study to the results of two previously published reports to confirm the 
models’ accuracy. 
Using only two samples of PELF per animal, the mixed effect model utilized in this study 
allowed for the estimation of the gamithromycin PK/PD values achieved in cattle diagnosed with 
BRD. The resulting simulated individual animal profiles were used to run a NCA in order to 
compare our model output to previous publications results. The PK parameter results obtained 
from that analysis are comparable to the values obtained previously (Huang, Letendre et al., 2010; 
Giguere, Huang et al., 2011) as shown in Table 7. Considering the differences in the physiological 
status of the study participants under investigation (healthy cattle in previous publications versus 
cattle diagnosed with BRD in this report) and the fact that this model under-predicts PELF, the 
resulting comparable PK parameters from this study demonstrates that our two compartment plus 
PELF effect compartment model was acceptable. However, the lower drug exposure found in the 
morbid animals in this study as compared to those utilizing healthy animals is noteworthy.  
Table 4 displays the estimated typical values of the compartmental model parameters. It 
should be noted that the VPELF is much larger than its actual physical volume in cattle because the 
role of this parameter in the model is a virtual compartment in which relatively low concentrations 
were observed for the administered dose. 
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Gamithromycin has been reported to be a low protein binding drug (26%) in the serum of 
healthy animals (Huang, Letendre et al., 2010). Protein binding was not an objective of this study 
and therefore was not evaluated. Variation in protein binding is expected to have minimal effect 
for drugs that display low protein binding. However, it is possible that alterations in the protein 
binding of the morbid animals in this study did have some effect on the PK differences we 
observed. Future studies focusing on determining the differences between healthy and diseased 
animals needs to be considered to determine if this was simply an effect of the modeling/sampling 
strategy utilized in this study or a difference truly exists.  
Much discussion is available in the literature surrounding the selection of the proper 
pharmacodynamic index to determine the optimal dosing of the macrolide class of antimicrobials. 
Contemporary thought on the newer ‘longer acting’ injectable macrolides in veterinary medicine 
is that the most important index is AUC/MIC. However, intense debate remains whether this 
should be measured and reported for plasma (Toutain, 2009; Papich, 2014), at the site of infection 
(Amsden, 2001; Evans, 2005) or both (Rodvold, George et al., 2011). Although not statistically 
significant, the marginally significant association between plasma PKPD indices and treatment 
outcome (P=0.10) would seem to substantiate the claims of using plasma drug concentrations. 
However, we did observe a significant association between PELF AUC24/MIC and treatment 
outcome (P=0.04) with P multocida suggesting that both plasma and PELF are correlated with 
treatment outcome. This finding is not surprising given the fact that the drug in the PELF is derived 
from and thus correlated with the drug in the plasma. However, completely ignoring the PELF 
compartment and confining interpretation to plasma alone could be misleading, especially when 
considering drugs with very extensive tissue distribution such as gamithromycin and other 
macrolide class antibiotics. 
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Prior to the initiation of the study gamithromycin did not have clinical breakpoints 
determined by the CLSI. However, since the conclusion of the live phase of this study 
gamithromycin breakpoints have been reported for M haemolytica, P multocida, and H somni at 
≤4.0, 8.0, ≥16.0 µg/mL for susceptible, intermediate, and resistant, respectively. The biphasic 
population of bacteria cultured from cattle displaying signs of BRD in this report fit those 
breakpoints. Conversely, in this study, there seemed to be little association between the in vitro 
determined MIC and treatment outcome, especially for P multocida (Table 7). Several authors 
have noted differences between the MIC determined in vitro and the MIC determined in the more 
physiologically relevant matrix, serum (Evans, 2005; Mitchell, McKellar et al., 2012; Mitchell, 
Goh et al., 2013). It remains a possibility that the lack of association, in this study, between 
reported MIC and treatment outcome could be due to a similar phenomenon.  
Several cattle yielded multiple isolates of M haemolytica and P multocida from either NPS 
or BAL, selection of isolate MIC was performed by choosing the isolate with the highest MIC at 
time 0 (Table 6). Therefore, PD indices reported in this study are likely to represent worst case 
scenarios as the results of this trial are also confounded by on arrival treatment allocation. Giguere 
et al. reported MIC90 values of 0.5 and 1.0 µg/mL for M haemolytica and P multocida in 2011 
(Giguere, Huang et al., 2011). Using those MICs would have certainly resulted in much different 
PD indices.  
Reported herein were the AUC/MIC ratios for both PELF and plasma, as well as the other 
standard PKPD indices (CMAX/MIC, T>MIC). Although minimal statistical differences were 
observed, our findings indicate that for both M haemolytica and P multocida, a longer drug 
exposure was more closely related to a successful treatment outcome. While some small 
differences in exposure were observed, it is unlikely that these differences substantially contributed 
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to the difference in clinical outcome. However, it is important to keep in mind that due to small 
sample size, there was a large amount of variability in the data which could contribute to the lack 
of statistical significance.  
Additionally, given the small numerical difference between success and failure PD indices, 
it seems that there are likely many factors beyond PK, PD, and MICs that contribute to the success 
of a treatment regimen. For example, the immunological status of the animal and the 
environmental conditions that the animal is subjected to undoubtedly also play a role in disease 
outcome. It has been shown that some macrolides have anti-inflammatory and immunomodulatory 
effects in addition to antimicrobial activity. Tulathromycin, a semi-synthetic macrolide of the 
subclass triamilide, has been extensively researched in this area (Fischer, Beatty et al., 2011; Er & 
Yazar, 2012; Fischer, Beatty et al., 2013; Fischer, Duquette et al., 2014; Duquette, Fischer et al., 
2015). Azithromycin, a macrolide of the same subclass as gamithromycin, has recently been shown 
to exert anti-inflammatory properties on lung epithelial cells in humans (Kitsiouli, Antoniou et al., 
2015). While data specific to gamithromycin is currently lacking in this area, it is possible that 
anti-inflammatory activity similar to that of azithromycin and tulathromycin could have facilitated 
a “self-cure” in this study. This should be further considered, especially considering the high 
treatment success rate observed in this study given the isolation of many resistant organisms as 
shown in Table 6.  
There appears to be an over-representation of resistant P multocida isolates in the MM 
treatment group. This is likely explained by the fact that gamithromycin was utilized for both mass 
medication and treatment in this study, a practice that is not common in the field. The reasoning 
for the lack of resistant M haemolytica in the MM group is not clear and deserves further attention 
in future studies.  
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Another layer of complexity must also be appreciated; there remains a possibility that 
bacteria other than M haemolytica and P multocida are responsible wholly, or in part, for the 
treatment failures. While H somni was isolated (data not shown), it was present very infrequently. 
It is possible that another resistant pathogen is contributing to the clinical signs associated with the 
BRD cases in this study. 
This report is, to the authors’ knowledge, the first of its kind in the veterinary literature, to 
perform such a large PK/PD examining drug concentrations in PELF within a group of cattle 
experiencing naturally occurring BRD. Although challenged by sample size limitations of 
ultimately diseased animals, a compartmental PK model was developed to which the sparse 
clinical data from this trial were successfully fit. Therefore, complete concentration-time profiles 
were simulated for the central and PELF effect compartment for each animal in order to determine 
PK/PD indices for M haemolytica and P multocida unique to each animal in this study. The 
findings from this study indicate that PK variability in cattle diagnosed with BRD seems at least 
as important as the MIC of M haemolytica or P multocida. Additionally, further consideration 
should be paid to other possible bacterial pathogens in association to BRD. 
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 Figures and Tables 
 
Score Description 
0 No abnormal signs 
1 
Slower than pen mates but still perks up when approached; does not appear 
weak; actively follows movements with raised head 
2 
Stands with head lowered; perks up when approached but returns to depressed 
stance; moves slowly and falls to back of group; may display signs of weakness 
such as incoordination 
3 
Obviously very weak; difficulty in moving with group; raises head only when 
approached closely 
4 Moribund, unable to rise 
Table 3.1 - Description of clinical scoring criteria used for daily clinical observations of feeder 
cattle to assist in diagnosis of bovine respiratory disease. Clinical scoring was performed by a 
veterinarian masked to study treatment allocation. 
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N 0 hr 12 hr 24 hr 120 hr 
8 BAL/Plasma/NPS Plasma Plasma BAL/ Plasma/NPS 
9 Plasma/NPS BAL/Plasma/NPS Plasma BAL/ Plasma/NPS 
9 Plasma/NPS Plasma BAL/ Plasma/NPS BAL/ Plasma/NPS 
Table 3.2 - Sampling scheme for bronchoalveolar lavage (BAL), deep nasopharyngeal swabs 
(NPS), and plasma in cattle diagnosed with bovine respiratory disease (BRD). The top row is hours 
after treatment, 0 hr is just prior to treatment with gamithromycin. The number of cattle enrolled 
in each collection scheme is represented in the first column (labeled N). 
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 Control (%) 
Mass Medicated 
(%) 
Total (%) 
Morbidity from BRD 17/90 (18.9) 9/90 (10.0) 26/180 (14.4) 
Mortality from BRD 0 0 0 
BRD Treatment 
Failure 
2/17 (11.8) 2/9 (22.2) 4/26 (15.4) 
Table 3.3 - Summary comparison of morbidity, mortality, and treatment failure rates of bovine 
respiratory disease among feedlot cattle allocated to either sham injection or mass medication with 
gamithromycin at 6 mg/kg. Treatment for BRD was also with gamithromycin at the time of BRD 
diagnosis by a veterinarian. The numerical differences were not statistically significant. (% = 
percentage of subjects) 
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  Units Estimates 
V L 183 
k10 1/hr 1.84 
Ka 1/hr 8.83 
k12 1/hr 7.09 
k21 1/hr 0.26 
k13 1/hr 0.98 
k31 1/hr 0.02 
VPELF L 201 
Table 3.4 –Population pharmacokinetic parameter estimates following administration of 
gamithromycin administered at an average dose of 6 mg/kg subcutaneously for the treatment of 
acute bovine respiratory disease.  
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  M haemolytica P multocida 
 Parameter Success (±SE) Failure (±SE) Success (±SE) Failure (±SE) 
Plasma AUC24/MIC 1.32 (±0.1) ‡ 0.67 (±0.59) ‡ 1.24 (±0.41) 0.72 (±0.42) 
AUC∞/MIC 3.49 (±0.4) ‡ 1.78 (±1.55) ‡ 3.21 (±1.07) 1.91 (±1.12) 
CMAX/MIC 0.09 (±0.01) ‡ 0.04 (±0.037) ‡ 0.08 (±0.03) 0.04 (±0.03) 
PELF AUC24/MIC 31.5 (±4.4) 24.6 (±22.4) 31.0 (±9.8)* 22.4 (±11.7)* 
AUC∞/MIC 205 (±29) 164 (±150) 209 (±67) 148 (±77) 
CMAX/MIC 1.86 (±0.26) 1.45 (±1.32) 1.83 (±0.58) † 1.32 (±0.69) † 
T>MIC 77 (±10) 44 (±44) 56 (±19) 44 (±25) 
Table 3.5 – Pharmacokinetic/pharamcodynamic indices for cattle treated with gamithromycin for 
acute bovine respiratory disease (mean (±SE)). Parameter comparisons are by pathogen (cultured 
at time 0) and treatment outcome within either plasma or the effect compartment, PELF. Values 
are calculated as free unbound drug using 26% protein binding from a previous study (Huang, 
2010). (* P = 0.04; † P = 0.07; ‡ P = 0.10) 
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CON  MM 
ID M haemolytica P multocida ID M haemolytica P multocida 
102 - - 150 1.0 - 
104 ≥16.0 - *195 - ≥16.0 
106 - ≥16.0 204 1.0 ≥16.0 
116 - 0.5 206 1.0 ≥16.0 
118 - 0.5 209 - ≥16.0 
126 - 0.5 *212 - ≥16.0 
174 1.0 - 213 - ≥16.0 
175 1.0 0.5 218 - ≥16.0 
*222 1.0 1.0    
224 - - *Treatment failure 
- = culture yielded no isolate 225 1.0 1.0 
229 1.0 - 
*236 - 1.0 
240 - - 
241 1.0 - 
243 1.0 1.0 
245 - - 
Table 3.6 – Minimum inhibitory concentration (µg/mL) comparison of time 0 isolates from both 
PELF and NPS isolates by treatment group. The single isolate with the highest MIC is reported for 
each calf (four calves yielded no isolates at time 0) 
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 Huang et al. Giguere et al. Current study 
 Plasma Plasma PELF Plasma PELF 
No. animals 32 30 30 26 26 
CMAX (µg/mL) 0.27 0.43 4.61 0.13 (±0.003) 3.04 (±0.09) 
AUC0-∞ (µg*h/mL) 8.28 7.95 348 5.4 (±0.13) 340 (±12) 
Cl (mL/hr/kg) 654* 830* - 1140 (±27) - 
V (L/kg) 56.9* 94.2* - 97.4 (±2.4) - 
MRT (hr) 41.3* 43.1 71.1 52.8 (±0.18) 79.0 (±0.29) 
Table 3.7 – Comparison of the current study models simulated output of pharmacokinetic 
parameters to previously published work by noncompartmental analysis. The label dose of 6 mg/kg 
subcutaneously was administered in each study. Values of CMAX and AUC0-∞ are reported as total 
drug since neither publication corrected for protein binding. (± SE where available; *Calculated 
from extrapolation of graphical data in manuscript 
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Figure 3.1 – Schematic representing the final pharmacokinetic model for the two compartment 
plus PELF effect compartment for concentration of gamithromycin in feedlot cattle diagnosed with 
bovine respiratory disease.  
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Figure 3.2 – Goodness of fit plots for model predicted data versus actual observed data from two 
previously published studies (Huang, Letendre et al. 2010; Giguere, Huang et al. 2011) and data 
obtained from personal communication with one of the co-authors (RKT). 
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Figure 3.3 – Full simulated time concentration curves for plasma and PELF. Curve comparisons 
are by treatment outcome, error bars represent standard error. Statistical comparison yielded no 
significant differences between outcomes in maximum concentration (plasma P=0.12, PELF 
P=0.22). 
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Figure 3.4 – Frequency distribution of clinical isolates of Mannheimia haemolytica (n=287) and 
Pasteurella multocida (n=257) MIC to gamithromycin cultured from bronchoalveolar and 
nasopharyngeal samples from cattle diagnosed with bovine respiratory disease. Samples were 
collected at time 0, 12 hrs, 24 hrs, and 120 hrs post treatment.  Numbers above bars represent 
isolate number at that respective MIC dilution. 
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Figure 3.5 - Bivariate histogram of MIC distribution of Mannheimia haemolytica and Pasteurella 
multocida cultured from bronchoalveolar and nasopharyngeal samples just prior to treatment (time 
0) for bovine respiratory disease in 26 head of cattle (4 calves did not yield an isolate at time 0).   
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 Abstract 
The objective of this study was to compare the results of gamithromycin MIC testing, as 
determined by broth microdilution, with genomic analysis for the determination of macrolide 
resistance genes, in genetically similar clinical strains of Mannheimia haemolytica isolated from 
feeder cattle experiencing clinical symptoms of bovine respiratory disease (BRD). Feedlot cattle 
were monitored for signs of BRD for 28 days in a randomized clinical trial. As many as 12 isolates 
of M. haemolytica from each culture sample were subjected to MIC determination and genomic 
analysis for the determination of the macrolide resistance genes erm(42), msr(E), and mph(E). 
Genotype served as the gold-standard comparator test for susceptibility categorization in a two by 
two table. Twenty-six cattle were diagnosed with BRD and contributed 276 clinical strains of M. 
haemolytica for gamithromycin MIC testing. A very high sensitivity (100%), specificity (97.4%), 
and accuracy (98.2%) was observed in the susceptibility categorization of gamithromycin 
sensitivity for the M. haemolytica that were isolated in this study.  Additionally, the positive 
(resistant) predictive value and negative (susceptible) predictive values of the test for this 
population were both quite high at 94% and 100%, respectively. In this study, WGS was utilized 
to compare the results of resistance genotype to the MIC categorization, or phenotype, as 
determined by broth microdilution technique. The broth microdilution technique proved to be a 
highly accurate and precise test for gamithromycin susceptibility of M. haemolytica in this 
population of cattle.  
 Key words:  
bovine respiratory disease, feedlot cattle, antimicrobial resistance, gamithromycin 
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 Introduction 
Antimicrobial susceptibility testing is currently the test of choice when a clinician is faced 
with choosing an antimicrobial regimen to treat difficult to cure bacterial infections. Additionally, 
much attention is paid in the literature and media to antimicrobial resistance trends as measured 
by these testing procedures in both human and animal populations. One of the more common 
antimicrobial susceptibility testing methods is MIC testing by a broth microdilution. The MIC is 
the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism 
in a broth (or agar) dilution susceptibility test.2 In veterinary medicine, the testing methods and 
interpretive criteria have been standardized by the CLSI and are described in VET01-A4.2  
A topic of recent interest is the ability of these testing methods to demonstrate repeatable 
and accurate results using genetically similar clinical isolates from the same or different animals. 
In other words, if there was a clonal expansion of a given bacteria in a population of animals, 
would the results of such testing be equal across all isolates? There are few publications in the 
veterinary literature investigating the repeatability or accuracy of MIC testing as compared to the 
genotyping of specific antimicrobial resistance elements. One recently published study 
investigated the identification of antimicrobial resistance genes contained in Escherichia coli with 
the results of MIC testing and found a high correlation between the two methods.20 
Considerable research has focused on antimicrobial resistance within the arena of bovine 
respiratory disease (BRD). Bovine respiratory disease is often cited as the number one area of 
economic loss to the beef industry, with estimates of annual global losses of up to $3 billion US 
dollars being reported previously.21 The disease is the result of a complex interaction of stressors, 
viruses, and bacterial pathogens. The bacteria most often implicated in the pathogenesis of BRD 
are Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. The epidemiology 
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and antimicrobial resistance of these pathogens has been extensively studied yet many questions 
remain regarding host-pathogen interactions. 
Recently, a research group utilized serotyping along with PFGE for the characterization of 
M. haemolytica isolated from the nasopharynx of cattle13. Although repeatability of MIC testing 
was not an objective of the study, they did report finding that isolates sharing the same serotype 
and resistance phenotype tended to cluster together in dendrogram analysis. Even though indirect 
and of lower power, this report does lend some evidence to the repeatability of MIC testing.  
To the authors’ knowledge no other reports on the accuracy of MIC, as compared to WGS 
in genetically similar BRD isolates exists within the veterinary literature. Owing to the paucity of 
this type of data, the objective of this study was to compare the results of gamithromycin MIC 
testing, as determined by broth microdilution, with genomic analysis for the determination of 
macrolide resistance genes, in genetically similar clinical strains of M. haemolytica isolated from 
either nasopharyngeal swabs (NPS) or bronchoalveolar lavage fluid (BAL) of feeder cattle 
experiencing clinical symptoms of bovine respiratory disease (BRD). 
 Materials and methods 
 Animals and husbandry 
One hundred and eighty cattle perceived to be at a high risk (lightweight (165-269 kgs), 
commingled, and long transportation) for developing BRD were sourced from Athens, Tennessee 
(n=60), Richmond, Kentucky (n=60), and Maryville, Missouri (n=60) as part of another study.3 
All sources contained commingled steers and bulls of multiple origins and mixed breeds. This 
study was approved by the Kansas State University Institutional Animal Care and Use Committee.  
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 Treatment allocation 
Cattle were randomized to either treatment for control of BRD, also known as mass 
medication (MM), with gamithromycin (6 mg/kg subcutaneously in the neck) or a sham injection 
of saline (CON) administered upon arrival to the feedlot in Manhattan, KS. Allocation was 
randomized within source (two pens per source (MM and CON) for a total of six pens in the study).  
 Clinical scoring and disease diagnosis 
Daily pen observations were performed by a veterinarian masked to treatment allocation 
and case outcome utilizing a previously published clinical scoring system.3 Diagnosis of BRD was 
determined based on cattle having a rectal temperature of ≥40.0˚C (≥104.0˚F) and a clinical score 
of ≥1 (general signs of depression and weakness). Cattle assigned a clinical score of ≥1 but not 
meeting the rectal temperature requirements were returned to their home pen without treatment 
and further observation.  
 Sampling allocation and collection procedures 
The day of BRD diagnosis served as Day 0 for each calf and included either a bilateral 
NPS collection, BAL collection, or both as determined by a randomized sample collection scheme 
utilized to meet the objectives of another study.3  Samples collected on Day 0 were collected just 
prior to treatment with gamithromycin and at 12 or 24 hours post administration. All cattle had 
both NPS and BAL collected at 120 hours post-administration of gamithromycin. The veterinarian 
responsible for clinical scoring was not present for treatments and procedures performed at the 
chute and therefore remained masked throughout the duration of the study period. Nasopharyngeal 
swabs and BAL fluid were immediately sent for bacterial culture. 
The BAL procedure was performed on non-sedated, manually restrained cattle. The BAL 
tubea was introduced into the trachea via the nasal passage and advanced blindly until wedged into 
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a deep bronchus. Sterile saline (240 mL) was infused in 60 mL aliquots and aspirated immediately 
after each aliquot, starting with the second aliquot. Recovered BAL fluid was divided evenly 
among four 50 mL centrifuge tubes, then placed on ice and centrifuged in the feedlot laboratory. 
Following centrifugation, one randomly selected cell pellet was resuspended in liquid Amies 
media and submitted for bacterial isolation. The BAL tubes were cleaned and sterilized by gas 
plasma sterilization before the next collection procedure to prevent cross contamination.  
Nasopharyngeal swabs were collected from both nares by a veterinarian trained in the 
procedure utilizing a previously described method.3  After collection, each swab was placed in 
individual liquid Amies media and transported on ice for bacterial culture and isolation.  
 M. haemolytica isolation and MIC determination  
Nasopharyngeal swabs and BAL samples were plated directly onto trypticase soy + 5% 
blood, chocolate, and MacConkey agar plates and incubated in 5% CO2 at 37˚C for 18-24 hours. 
Up to 12 colonies displaying growth characteristics typical of M. haemolytica were further isolated 
in pure culture from each calf. Confirmation of isolate identity was performed with MALDI-TOFb 
and frozen for subsequent susceptibility testing. 
Gamithromycin susceptibility testing of M. haemolytica isolates was determined by 
personnel masked to treatment group by a broth microdilution technique utilizing frozen panelsc. 
The custom plates contained gamithromycin at concentrations ranging from 0.03 to 16 µg/mL. 
Suspensions of M. haemolytica were prepared and susceptibility plates inoculated as per VET01-
A4, section 12.1.2 Briefly, isolates were cultured on chocolate agar and incubated with increased 
CO2 at 37˚C for 18-20 hours. Suspensions of M. haemolytica equivalent to 0.5 McFarland standard 
were made by suspending 3 to 5 isolated colonies from each plate, into 5 mL of demineralized 
water. Mueller-Hinton broth tubes (11 mL) were then inoculated with 140 µl of the resulting M. 
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haemolytica suspensions. A 12 channel pipette was used to dispense 50 µl of this suspension into 
each of 12 wells in the plate, such that the susceptibility of 8 strains could be evaluated per plate. 
Plates were sealed with seal strips and incubated at 37˚C for 18-20 hours at which time the plates 
were visually inspected and MIC values determined by noting the lowest concentration of 
antibiotic that completely inhibited growth. Interpretation of susceptible, intermediate or resistant 
was determined using clinical breakpoints established by CLSI. Gamithromycin breakpoints have 
been reported for M. haemolytica, Pasteurella multocida, and Histophilus somni at ≤4.0, 8.0, ≥16.0 
µg/mL for susceptible, intermediate, and resistant, respectively (RK Tessman, Merial, personal 
communication). Staphylococcus aureus ATCC 29213 was used for quality control in this study. 
 M. haemolytica genomic sequencing, bioinformatic, and phylogenetic analyses 
A manuscript describing the sequencing and analyses of the isolates described in this study, as 
well as an additional 800 isolates is currently in production.  Briefly, single colony isolates of M. 
haemolytica were grown overnight in 1 ml of Brain Heart Infusion (BHI) broth with no shaking in 
96 deep well blocks.  DNA extractions were performed with DNA kits according to the 
manufacturer’s instructionsd.  The DNA samples were quantified with a fluoromotere. DNA 
libraries were constructed with original A Indices kits and sequenced on a DNA sequencerf.  A 
minimum of 10X genome coverage was obtained for each isolate sequenced.  Each library was 
mapped to an available closed circular M. haemolytica genome available in GenBank 
(CP004752),10 using the Bowtie 2 mapping algorithm for SNP identification. Bootstrapped 
Neighbor-Joining phylogenetic trees were constructed from concatenated SNP genotypes of each 
isolate using an F84 substitution model in PHYLIP (version 3.69).6  The trees were viewed with 
Dendroscope (version 3.2.10).11 Additionally, the raw sequence reads were mapped to previously 
described integrative and conjugative elements (ICEs) identified in the genomes of two M. 
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haemolytica isolates (GenBank # CP004752 and CP005383.1), and one P. multocida (GenBank # 
NC_016808).4 This was performed to identify antibiotic resistance genes within the mapped 
libraries that were homologous to those harbored on the reference ICEs, including the macrolide 
resistance genes erm(42), msr(E), and mph(E).    
 Comparing gamithromycin MICs to the presence or absence of macrolide resistance genes 
erm(42), msr(E)-mph(E)  
 In order to compare the susceptibility determination (susceptible/intermediate or resistant), 
genotype, as defined as the presence or absence of macrolide resistance genes erm(42) and/or 
msr(E)-mph(E), was considered the gold standard.  It was assumed that the presence of the erm(42) 
and/or msr(E)-mph(E) should result in the expression of phenotypic resistance. As such, the 
phenotype as determined by MIC testing was compared to the presence or absence of erm(42) 
and/or msr(E)-mph(E) for all M. haemolytica isolates. 
 A two by two table was constructed as shown in Table 1 to calculate MIC test sensitivity, 
specificity, and positive and negative predictive values as compared to the gold standard 
(genotype). Sensitivity was calculated as True Positive / (True Positive + False Negative). 
Specificity was calculated as True Negative / (False Positive + True Negative). Positive (resistant) 
predictive value was calculated as True Positive / (True Positive + False Positive). Negative 
(susceptible) predictive value was calculated as False Negative / (False Negative + True Negative). 
The accuracy was calculated as (True Positive + True Negative) / Total of Isolates. The sensitivity 
in this study was defined as the proportion of the isolates that were truly resistant by genotyping 
that were correctly identified as resistant by MIC determination. The specificity was defined as the 
proportion of truly susceptible isolates that were correctly identified as susceptible. The positive 
predictive value, for resistance, was defined as the probability that an isolate was truly resistant if 
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the MIC testing determined it resistant. The negative predictive value, for susceptibility, was 
defined as the probability that an isolate was truly susceptible if the MIC testing determined it 
susceptible. Further, for the purposes of this publication, a minor error was defined as an 
intermediate result from MIC testing in an isolate with or without genotypic resistance. A major 
error was defined as a MIC determination of resistant without a genotype for resistance, and a very 
major error was defined as an MIC determination of susceptible with a genotype for resistance. 
  Analysis 
All samples were entered into a laboratory information management system (LIMS) for 
sample accountability and to ensure biologic samples were not inadvertently lost to follow-up. 
Output was immediately either exported or transcribed into digital spreadsheets for storage and 
interpretation. Due to the nature of the data, limited sample size, and objective of this publication, 
statistics were limited to descriptive summary and interpretation only. 
 Results 
Twenty-six cattle were diagnosed as having BRD during the course of the study. Fourteen 
of the 26 cattle (53.8%) diagnosed with BRD yielded a positive M. haemolytica (presence of at 
least one isolate) culture from either the nasopharynx or the lungs at some point in the sampling 
period. Eleven of the 14 cattle were from the CON group and the remaining three cattle were from 
the MM group. The range of isolates from both sample sources (24 maximum possible isolates) 
per calf per time point was from 0 – 24 isolates with a median of 6 isolates/calf.  
In total, 287 isolates of M. haemolytica were collected from the NPS and BAL samples 
throughout the study. The MIC distribution for all of the isolates collected in this study can be 
found in Figure 1. As many as 12 colonies were selected per culture per sample source (NPS or 
BAL), therefore, Figure 1 represents MIC determination of several isolates per calf.  
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Among the cattle from which M. haemolytica was cultured, 10 of 14 yielded isolates by 
NPS and/or BAL samples prior to treatment (time 0 hr) with gamithromycin; three at 12 hours, 
zero at 24 hours, and nine cattle gave positive culture results at 120 hours post treatment. The 
relative frequency of isolation of M. haemolytica, and the number of cattle sampled at each time 
point, are displayed for each sample source, and genetic subtype in Table 2. 
The 287 isolates were subjected to WGS, however, 11 isolates were removed from further 
analysis due to difficulty late in the sequencing process. Based on SNP profiles identified from 
WGS, the remaining isolates fell into one of two distinct phylogenetic clades.  Each clade was 
further divided into subtypes based on clustering patterns and strong bootstrap support (Figure 2).  
Isolates placed within subtypes were accepted as highly related by their SNP profiles. 
Minimum inhibitory concentration by genetic subtype can be found in Table 3. Five of the 
clonal populations had MIC determination spread across the susceptible, intermediate, or resistant 
categories (1f pre-treatment, and 1i, 2b, 2c, and 2d post-treatment). Comparison of the phenotype 
to the genotype was performed for all of the 276 M. haemolytica isolates. There were 16 
discrepancies (16 individual isolates from 5 cattle) between phenotypic MIC determination and 
genotype and each were from isolates collected post-treatment. The animal identification number, 
sample source (BAL or NPS), treatment group, M. haemolytica subtype, MIC determination, and 
status of the msr(E)-mph(E) for each of the isolates that had a mismatch of phenotype and genotype 
may be found in Table 4. Interestingly, each of the isolates which displayed resistance that were 
not from the 2b subtype (a single isolate from each of subtype 1f, 1i, 2c, and 2d) reverted to 
susceptible (MIC=1 µg/mL, data not shown) on subsequent MIC testing as part of another 
experiment. The repeated testing (isolates frozen between testing from late Fall of 2013 to early 
spring of 2015) for that experiment was targeted at the isolates with an MIC of 16 µg/mL. 
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However, given that the initial call was resistant, no lab errors could be identified, the retesting 
was biased and un-blinded, and not all isolates could feasibly be retested, they remained to be 
interpreted as resistant for this publication. 
The erm(42) gene was not found in any of  the M. haemolytica isolated in this study. The 
isolates in 1f and 1i were predominately susceptible with an MIC value of 1.0, the one isolate from 
each of these two subtypes that resulted in an MIC of ≥16.0 appears to be either misclassified (due 
to the absence of the msr(E)-mph(E) genes) by MIC testing or displayed phenotypic resistance 
through another mechanism. Isolates of subtype 2b (n=88) resulted in 86 resistant (≥16.0 µg/mL) 
and two susceptible (1.0 µg/mL) MIC determinations. The calf that yielded the two susceptible 
isolates (post-treatment) also had 17 other 2b subtype isolates collected post-treatment that were 
phenotypically resistant. Interestingly, of those 19 2b isolates, three of them did not contain the 
msr(E)-mph(E) genes; two of those three 2b isolates lacking resistance genes resulted in the 
susceptible determinations described above, and the third isolate not containing the resistance 
genes had an MIC of ≥16.0 µg/mL. All other isolates of the 2b subtype that were called resistant 
had the msr(E)-mph(E) genes, and were expressing it phenotypically.  
Isolates of the subtype 2c (n=13) were predominately susceptible, with MICs of 1.0 (10 
isolates), 2.0 (1 isolate), and 4.0 µg/mL (1 isolate). The one 2c isolate that resulted in an MIC of 
≥16.0 µg/mL also did not contain the macrolide resistance genes. The isolates in subtype 2d (n=18) 
were scattered across each of the categories, with six isolates in the susceptible (1.0 µg/mL), eleven 
isolates in the intermediate zone (8.0 µg/mL), and one isolate determined to be resistant (≥16.0 
µg/mL). The subtype 2d were the only isolates returning a result of intermediate.  Once again, all 
of the isolates from the subtype 2d lacked the macrolide resistance genes evaluated in this study. 
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The two by two table populated with the M. haemolytica isolate results from this study can 
be found in Table 5. Additionally in Table 5 are the calculated sensitivity, specificity, accuracy, 
positive predictive value, negative predictive value, minor error, major error, and very major errors 
rates. 
 Discussion 
 We report a positive M. haemolytica culture rate (53.8%) similar to previously published 
study.19 In that report they found 65% of samples from nasal swabs, transtracheal washes, or both 
sampling sources to contain at least one M. haemolytica isolate across sampling time points in a 
study of newly received beef bulls at French fattening operations.  
The data reported herein found little variability in MIC categorization as determined by a 
broth microdilution technique when compared to genotype. Of the 276 M. haemolytica isolates in 
this report, only 16 isolates (5.8%) appear to be misclassified by comparing the phenotype to the 
genotype. That can be further broken down into a minor error rate of 4.0%, a major error rate of 
1.8%, and no very major errors. Further, our assumption was that bacteria with the genotype for 
resistance would result in the expression of phenotypic resistance and in this investigation it was 
found to be true in every instance. All 85 isolates found to contain the macrolide resistance genes 
msr(E)-mph(E) had gamithromycin MIC determinations of ≥16 µg/mL. 
All of the minor errors arose from a single subtype isolated from one calf. These were in 
subtype 2d from the post-treatment samples and as can be seen in Table 2, are spread across all 
three categories (S, I, and R). Without the use of molecular techniques it would be difficult to 
determine if there was indeed a correct or incorrect categorization in this subgrouping. In a recent 
study, researchers reported six isolates of M. haemolytica that contained the erm(42) but not the 
msr(E)-mph(E) genes to have an MIC range of 4 (n=1) to 8 (n=5) µg/mL.17 However, with the 
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techniques used in this study it was determined that none of the 2d isolates contained the erm(42) 
or msr(E)-mph(E) genes. 
There are several possible reasons for the discrepancy observed in the 2d isolates and the 
other (1f, 1i, 2b, 2c) discrepant results in this study. First, it is possible that another mechanism of 
resistance, such as a de novo mutation, was present in some of the isolates in this subtype which 
was undetected by our techniques. In a recent report, one M. haemolytica (strain Mh14717) and 
three P. multocida (strains Pm14424, Pm14421, Pm14426) that were confirmed negative for the 
erm(42) and msr(E)-mph(E) displayed high macrolide resistance.16 Those isolates were from the 
field and collected from cattle within Europe from 2010 – 2013. The methodology used in that 
investigation utilized DNA extraction and Multiplex PCR to confirm the absence of previously 
reported macrolide resistance genes, and subsequent genome sequencing to attempt to determine 
the mechanism of resistance. In all strains they reported that the observed resistance was conferred 
by 23S rRNA mutations and speculated that it was from de novo mutations followed by selective 
pressure (administration of macrolide antimicrobial). The isolates in the present study that were 
resistant and intermediate to gamithromycin but did not contain the erm(42) and msr(E)-mph(E) 
genes were investigated for mutations (post hoc) in 23S rRNA and no such mutations were found. 
It is possible that there are other factors or resistant elements not accounted for in this study that 
are responsible for the observed increase in MIC within these strains.  
Another possible explanation is regarding the fact that the MIC determination and DNA 
sequencing were performed independently at different points in time. Although both diagnostics 
utilized the same bacterial stock, it is possible that either a mixed culture of two different subtypes 
of M. haemolytica was present in the stock or the genotype of the strain drifted with culture passage 
resulting in the discrepancies observed.  
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A final hypothesis for the discrepancy between phenotype and genotype could be due to 
inherent variability in MIC determination. Even under ideal conditions MIC testing is reported to 
be subject to variability from sources such as inoculum, consistency of medium composition, 
incubation temperature and atmosphere, reading of the test, among others.7,15 Although a high 
degree of repeatability was observed in this current study, these limitations could help explain the 
variability that was observed, especially considering the sensitivity in MIC determinations that 
macrolides can display with even slight changes in pH and media composition.5,8,14,15  
Overall a very high sensitivity (100%), specificity (97.4%), and accuracy (98.2%) was 
observed in the MIC determination of gamithromycin susceptibility for the M. haemolytica that 
were isolated in this study.  Additionally, the positive predictive value and negative predictive 
values were both high at 94% and 100%, respectively. Positive and negative predictive values are 
dependent upon the prevalence of resistance in the dataset and can be limited when resistance is 
not present in the isolates tested.12 Resistant strains were well represented in this study; therefore, 
these values can be considered as reliable indicators of the probability of the MIC determination 
of susceptibility to gamithromycin by broth microdilution technique being truly correct for M. 
haemolytica isolates in populations of cattle that are similar to those in this study. 
 Although no similar publications performing an accuracy assessment of MIC 
categorization of M. haemolytica using resistance genotype as a gold standard were found in a 
search of the literature, previous researchers have compared the accuracy of susceptibility testing 
by disk diffusion methods for both P. multocida and M. haemolytica using agar dilution testing 
methods as the gold standard.1 Considering the differences in MIC testing methodologies, 
comparing those results to these in the current study would be inappropriate. Further, their testing 
did not include an antimicrobial representing the macrolide class. However, it was their opinion 
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that the gold standard of choice would be to utilize molecular techniques to confirm the presence 
or absence of resistance mechanisms. 
 In a study similar to the one reported here, a high correlation between resistance genotype 
and resistance phenotype was observed.20 A macrolide similar to gamithromycin, azithromycin, 
was included in their testing panel and they reported a 100% sensitivity and specificity. However, 
they observed very low resistance rates, with only one of 76 strains of E. coli containing resistance 
genes to azithromycin. Although the organism in their study was E. coli and the antimicrobial 
panel was more extensive, we too report a similarly high correlation between antimicrobial 
resistance genotype and phenotypic expression in M. haemolytica for the macrolide 
gamithromycin. Other groups have reported similar high concordance between genotype and 
phenotype in human9,18 and porcine22 isolates using WGS. 
 Conclusions 
In this study, WGS was utilized to determine the presence or absence of the macrolide 
resistance genes msr(E)-mph(E). The resulting genotype was used as a gold-standard to compare 
the results of gamithromycin susceptibility testing by a broth microdilution technique. The MIC 
testing utilized in this study proved to be a highly accurate test for M. haemolytica sensitivity to 
gamithromycin in this population of cattle. This demonstrates that WGS may be effectively used 
to determine the presence or absence of the resistant genotype, and could serve as a reasonable 
alternative to phenotypic testing procedures. 
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 Figures and Tables 
 
Table 4.1 – Two by two layout of genotype and phenotype comparison used to calculate the 
sensitivity, specificity, and positive and negative predictive values of the minimum inhibitory 
concentration determinations for M. haemolytica isolates in this study. Genotype was determined 
using WGS and phenotype was determined via broth microdilution.* 
  Genotype 
  R I/S 
P
h
en
o
ty
p
e 
R 
True 
Positive 
False 
Positive 
I/S 
False 
Negative 
True 
Negative 
*R = Resistant; I/S = Intermediate/Susceptible 
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Table 4.2 – Number of cattle for which at least one M. haemolytica was isolated, by time point 
following diagnosis of bovine respiratory disease and treatment at time zero with gamithromycin. 
Isolates are reported by genetic subtype (left column) and as a total of all M. haemolytica isolates. 
The percentage (%) is equal to the number of cattle culture positive/the number of cattle sampled 
at each time point (N).* 
 Nasopharyngeal swab Bronchoalveolar lavage fluid 
Subtype 0 hr 12 hr 24 hr 120 hr 0 hr 12 hr 24 hr 120 hr 
1c 1 (4%) -  -  - - - - - 
1e 1 (4%) -  - - - - - - 
1f 1 (4%) -  - 2 (8%) - - - 1 (4%) 
1i 1 (4%) 1 (11%)  - 1 (4%) - 1 (11%) - - 
2b 3 (12%)  -  - 4 (15%) 2 (25%) - - 4 (15%) 
2c 2 (8%) 1 (11%)  - 1 (4%) - 1 (11%) - - 
2d 2 (8%) 1 (11%) - 1 (4%) - - - 1 (4%) 
Total 
11* 
(42%) 
3  
(33%) 
0 9 
(35%) 
2 
(25%) 
2 
(22%) 
0 6 
(23%) 
N 26 9 9 26 8 9 9 26 
* Ten cattle contributed eleven isolates at this time point (i.e. one calf contributed both a 1c and a 
2b and is therefore represented twice in this total) 
  
109 
Table 4.3 – MIC distribution for each genetic subtype of M. haemolytica as determined for isolates 
collected pre-treatment with gamithromycin (Pre-Tx) or isolates collected at 12 and 120 hours 
after treatment with gamithromycin (Post-Tx). The subtype in the left hand column represents the 
clade and subtype for each group of isolates. * 
  Minimum Inhibitory Concentration (µg/mL) 
Subtype Time Point ≤0.03 0.06 0.12 0.25 0.5 1 2 4 8 ≥16 
1c Pre-Tx - - - - - 1 - - - - 
Post-Tx - - - - - - - - - - 
1e Pre-Tx - - - - - 2 2 - - - 
Post-Tx - - - - - - - - - - 
1f Pre-Tx - - - - - 11 - - - 1 
Post-Tx - - - - - 19 - - - - 
1i Pre-Tx - - - - - 12 - - - - 
Post-Tx - - - - - 19 - - - 1 
2a Pre-Tx - - - - - 1 - - - - 
Post-Tx - - - - - - - - - - 
2b Pre-Tx - - - - - 42 - - - - 
Post-Tx - - - - - 2 - - - 86 
2c Pre-Tx - - - - - 24 - - - - 
Post-Tx - - - - - 10 1 1 - 1 
2d Pre-Tx - - - - - 22 - - - - 
Post-Tx - - - - - 6 - - 11 1 
*Pre-Tx = Pre-treatment; Post-Tx = Post-treatment 
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Table 4.4 – Sample source, treatment group, M. haemolytica subtype, MIC determination and 
status of resistance genes for each of the isolates whose genotype did not match their phenotype. 
(No isolates in this study contained the erm(42) gene).* 
 
Animal ID Sample 
Source 
Treatment Subtype MIC msr(E)-mph(E) 
104 NPS CON 1f ≥16 N 
175 NPS CON 1i ≥16 N 
222 NPS CON 2b ≥16 N 
206 NPS MM 2c ≥16 N 
243 
BAL CON 2d ≥16 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
BAL CON 2d 8 N 
NPS CON 2d 8 N 
*NPS = nasopharyngeal swab, BAL = bronchoalveolar lavage fluid; CON = control treatment 
group; MM = mass medication with gamithromycin 
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Table 4.5 – Two by two table of genotype versus phenotype test outcome for the M. haemolytica 
isolates in this study. A minor error was defined as an intermediate result from MIC testing in an 
isolate with or without genotypic resistance. A major error was defined as a MIC determination of 
resistant without a genotype for resistance, and a very major error was defined as an MIC 
determination of susceptible with a genotype for resistance. Calculated values are shown as 
percentages.* 
  
Sensitivity 100% 
Specificity 97.4% 
Accuracy 98.2% 
Positive Predictive Value 94% 
Negative Predictive Value 100% 
Minor error 4.0% 
Major error 1.8% 
Very major error 0% 
*R = Resistant; I/S = Intermediate/Susceptible 
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R 85 5 
 
I/S 0 186 
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Figure 4.1 – MIC to gamithromycin of M. haemolytica (n=276) from cattle treated for BRD. 
Isolates represent multiple isolates per calf, from multiple time points (0, 12, and 120 hours post 
administration of gamithromycin) collected from both nasopharyngeal swabs and bronchoalveolar 
lavage fluid. 
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Figure 4.2- Neighbor-Joining trees of M. haemolytica clades 1 and 2 based on genome-wide 
concatenated SNPs from 276 isolates.  Subtypes within the clades are denoted by lower case letters.  
Numbers beside internal nodes of the tree represent bootstrap percentage values from 100 pseudo-
alignments.  The scale bar represents substitutions per site within trees.  The genetic distance 
between clades 1 and 2 exceeds the genetic distance within the two clades and is not shown. 
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Abstract 84 
The first objective of this work was to describe gamithromycin susceptibility of Mannheimia 85 
haemolytica, Pasteurella multocida, and Histophilus somni isolated from cattle diagnosed with 86 
bovine respiratory disease (BRD), post-treatment and/or mass medication with this antimicrobial. 87 
The second objective was to characterize the macrolide resistance genes present in genetically 88 
subtyped M. haemolytica isolated from cattle that had either been treated on arrival for control of 89 
BRD (MM) or sham saline injection (CON). M. haemolytica (n=276), P. multocida (n=253) and 90 
H. somni (n=78) were isolated from feedlot cattle diagnosed with BRD. Determination of 91 
susceptibility to gamithromycin was performed by broth microdilution. Whole genome sequencing 92 
was utilized to determine the presence or absence of macrolide resistance genes in M. haemolytica 93 
isolates. Generalized linear mixed models were built for data analysis. Resistance was 94 
overrepresented by the 2b subtype of M. haemolytica. There was not a significant difference 95 
between MM and CON groups in regards to the likelihood of culturing a resistant or intermediate 96 
isolate of M. haemolytica or P. multocida. The likelihood of culturing a resistant or intermediate 97 
isolate of M. haemolytica differed significantly by state of origin and further investigation in this 98 
area is warranted. A single M. haemolytica genetic subtype correlated with nearly all of the 99 
observed resistance. Additional studies to elucidate the relationships between phenotypic and 100 
genotypic resistance and clinical response to antimicrobials are necessary to inform judicious use 101 
of antimicrobials in the context of relieving animal disease and suffering. 102 
 Key words:  103 
antimicrobial resistance, bovine respiratory disease, Mannheimia haemolytica, Pasteurella 104 
multocida, Histophilus somni 105 
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 Introduction 107 
Antimicrobial administration has been the mainstay for both the treatment and control of 108 
BRD for several decades. Considering the ability of bacteria to adapt and survive in changing 109 
environmental conditions, it comes as no surprise that the bacterial pathogens associated with BRD 110 
are now commonly found to be resistant to these antimicrobials.6 111 
Resistance to antimicrobials is either intrinsic or acquired. Intrinsic resistance is the 112 
inherent ability of a bacterium to resist the action of a particular antimicrobial agent or class of 113 
agents through characteristics that prevent the mode of action of the agent. For example; an 114 
anaerobic bacterium would be intrinsically resistant to the aminoglycosides because the bacterium 115 
would lack the oxidative metabolism necessary to transport the drug inside the cell, thus preventing 116 
the drug binding to the 30S ribosomal subunit and killing the bacteria. Acquired resistance comes 117 
from either a genomic mutation or through the acquisition of resistance genes via horizontal 118 
transfer (transduction, conjugation, or transformation).32 119 
Conjugation requires direct contact between the donor and recipient cell in order for 120 
transfer of DNA to occur. Typically the DNA is brought into the cell as a single strand and then 121 
converted to double-stranded DNA by the recipient cell. Within the last several years, the presence 122 
of integrative conjugative elements (ICE) have been recognized in bacteria of the Pasteurellacae 123 
family.12,22,25 These elements are mobile genetic elements that mediate their own excision from 124 
the host chromosome, form a circular intermediate and encode their own machinery to transfer 125 
themselves by conjugation, and are then able to integrate and replicate as a part of the host 126 
chromosome.32 127 
The first report on macrolide resistance at the molecular level among BRD pathogens was 128 
published in 2011.9 This was an investigation of field isolates of M. haemolytica and P. multocida 129 
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that were reported as highly resistant to lincosamides and moderately resistant to macrolides, a 130 
resistance phenotype commonly termed Type I MLSB. DNA sequence analysis revealed that none 131 
of the resistant isolates had mutations in their ribosomal protein or rRNA components (consistent 132 
with Type I MLSB phenotype), but all isolates were monomethylated on the 23S rRNA nucleotide 133 
A2058 which indicated that they had an erm gene. Continued genetic analysis suggested that this 134 
novel erm(42) gene had been acquired from other members of the Pasteurellaceae family and was 135 
a recent gene transfer to M. haemolytica and P. multocida. Further, they hypothesized that due to 136 
erm(42) bearing such little resemblance to members of the erm gene family (the closest being a 137 
39% identity in the core sequence) its divergence must have been an ancient evolutionary event 138 
predating the existence of MLSB antimicrobials. 139 
In a nearly simultaneously published report, researchers reported on three macrolide 140 
resistance genes found in a strain of P. multocida (strain 36950) isolated from a calf in a Nebraska 141 
feedlot in 2005.19 This particular strain had shown resistance to most antimicrobials approved for 142 
treatment of BRD and prior to this investigation, the mechanism of resistance had not been 143 
determined. Performing whole genome sequencing (WGS) and a series of cloning experiments 144 
they discovered three macrolide resistance genes, (the first of which was described previously9) 145 
erm(42), msr(E), and mph(E). The erm(42) gene codes for an rRNA methylase gene, the msr(E) 146 
gene codes for an ABC transporter protein, and the mph(E) gene codes for a macrolide 147 
phosphotransferase protein.19,25 The msr(E) and mph(E) genes are organized in an operon-like 148 
structure and separated only by a non-coding spacer sequence of 55 base pairs. 149 
Working further with the same strain of P. multocida (strain 36950) isolated from a 150 
Nebraska feedlot in 2005, it was found that the macrolide resistance genes were actually a small 151 
part of an ICE.25 Through WGS, these researchers described two resistance gene regions, termed 152 
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ICEPmu1 and ICEPmu2, which contained a total of 12 resistance genes. These two regions, among 153 
others, contained tetracycline resistance genes that had previously been reported to be present 154 
almost exclusively on plasmids; florfenicol and aminoglycoside resistance genes that have rarely 155 
been seen in BRD pathogens; and resistance genes (macrolide, gentamicin, spectinomycin, 156 
streptomycin, and β-lactam) novel to P. multocida. These findings led the authors to conclude that 157 
P. multocida is able to acquire resistance from other Gram-negative bacteria, incorporate it into its 158 
own DNA, and use these genes to phenotypically express resistance. 159 
A recent study investigated the effects of these three genes on the MICs of gamithromycin 160 
and tildipirosin.24 In both P. multocida and M. haemolytica they reported a pronounced increase 161 
in MICs to gamithromycin for those isolates containing msr(E)-mph(E) and a marked increase in 162 
MICs to tildipirosin for erm(42) containing isolates. The subset of isolates that harbored all three 163 
genes displayed increased MICs to both of the newer macrolides in their study. Similar work found 164 
the same to be true; greatly elevated MICs for tildipirosin and tilmicosin in the presence of erm(42) 165 
and greatly elevated MICs for tilmicosin, tulathromycin and gamithromycin in the presence of 166 
msr(E)-mph(E).28 These two studies remain the only publications to investigate the molecular 167 
effects of the macrolide resistance genes on BRD bacterial pathogen sensitivity to gamithromycin.  168 
Therefore, the objectives of this work were; first, to describe gamithromycin susceptibility 169 
of M. haemolytica, P. multocida, and H. somni isolated from cattle diagnosed with bovine 170 
respiratory disease (BRD), post-treatment and/or mass medication with this antimicrobial, and 171 
second, to characterize the macrolide resistance genes present in genetically subtyped M. 172 
haemolytica isolated from cattle that had either been treated on arrival for control of BRD (MM) 173 
or sham saline injection (CON). 174 
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 Materials and methods 175 
 Animals and treatment allocation 176 
As described previously, 180 cattle perceived to be at a high risk for developing BRD (165-177 
269 kgs) were sourced from three states within the United States as part of another study.7  The 178 
cattle were randomly allocated to receive either treatment for control of BRD (MM) with 179 
gamithromycin (6 mg/kg subcutaneously in the neck) or a sham injection of saline (CON) 180 
administered upon arrival to a research feedlot near Manhattan, Kansas. The treatments were 181 
assigned to cattle within state of source, yielding a total of six pens in the study. This study was 182 
approved by the Kansas State University Institutional Animal Care and Use Committee. 183 
 Clinical scoring and disease diagnosis  184 
Cattle were observed for symptoms of BRD once daily in their pen for 28 days by a 185 
veterinarian masked to treatment allocation. The diagnosis of BRD was determined based on a calf 186 
having a rectal temperature of ≥40.0˚C (≥104.0˚F) and a clinical score of ≥1 (general signs of 187 
depression and weakness).7 188 
 Sampling allocation and collection procedures 189 
The collection procedures of diagnostic samples from cases of BRD in this study have been 190 
described previously.7 Nasopharyngeal swabs (NPS) were collected, bi-laterally and pooled, 191 
immediately prior to treatment (0 hour) from all cattle diagnosed with BRD. Additionally, cattle 192 
were allocated to receive a bronchoalveolar lavage at either 0, 12, or 24 hours post treatment with 193 
gamithromycin. Cattle sampled by BAL at 12 and 24 hours also were simultaneously sampled by 194 
NPS. All cattle diagnosed with BRD were sampled by means of both BAL and NPS 120 hours 195 
after treatment administration. 196 
122 
 
 Bacterial isolation and MIC determination  197 
After collection, NPS and BAL samples were transported on ice where they were plated 198 
directly onto trypticase soy + 5% blood, chocolate, and MacConkey agar plates. The plates were 199 
incubated in 5% CO2 at 37˚C for 18-24 hours. Up to 12 colonies of M. haemolytica and up to 6 200 
colonies of both P. multocida and H. somni displaying growth characteristics typical of each were 201 
further isolated in pure culture from each calf. Isolate identity was confirmed with MALDI-TOFa 202 
and frozen for subsequent susceptibility testing. 203 
Susceptibility testing to gamithromycin was performed by personnel masked to treatment 204 
group by a broth microdilution technique as previously described.8 Staphylococcus aureus ATCC 205 
29213 was used for quality control in this study. Determination of susceptible (≤4 µg/mL), 206 
intermediate (8 µg/mL) or resistant (≥16 µg/mL) was based off of clinical breakpoints established 207 
for gamithromycin by CLSI (RK Tessman, Merial, personal communication). 208 
 M. haemolytica genomic sequencing, bioinformatic, and phylogenetic analyses 209 
The details of these methods have been previously reported.8 Briefly, extracted DNA was 210 
quantified and Illumina Nextera XT DNA libraries were constructed and sequenced (minimum 211 
10X genome coverage) on an DNA sequencerf. Resulting libraries sequences were individually 212 
mapped to an available closed circular M. haemolytica genome available in GenBank 213 
(CP004752).18 Bootstrapped Neighbor-Joining phylogenetic trees were constructed from SNP 214 
genotypes that were identified from the mapped sequences. Additionally, antimicrobial resistance 215 
genes were identified by mapping to previously described ICEs identified in two M. haemolytica 216 
isolates (GenBank # CP004752 and CP005383.1),18 and one P. multocida (GenBank # 217 
NC_016808)13 isolate. 218 
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 Analysis 219 
Intermediate and resistant isolates were lumped together to create a binomial outcome 220 
variable (either susceptible or intermediate/resistant) for purposes of analysis. Data were inputted 221 
into a statistical softwarec and generalized linear mixed models, fit by maximum-likelihood 222 
regression, were built to determine if there was an association between on-arrival treatment and an 223 
MIC determination of susceptible or intermediate/resistance. Treatment group, time, and state of 224 
origin were modeled as fixed effects and random variables were included to account for clustering 225 
of isolates within cattle and cattle within individual pens for the analysis of M. haemolytica data. 226 
Models including state of origin would not converge for P. multocida data. Neither models would 227 
converge when a treatment by sampling time point interaction was included. All attempts to model 228 
H. somni data were unsuccessful due to a low isolation count. A corresponding P-value of ≤0.05 229 
was considered significant. 230 
 Results 231 
As previously reported, 26 cattle met the clinical criteria for BRD during the course of the 232 
study.7 There were only four first-treatment failures, two each from the MM and CON groups. The 233 
number of days on study at the time of BRD diagnosis ranged from 4 – 21 days, with a mean and 234 
median of 14 days. Of the four failures, two yielded a M. haemolytica isolate over the sampling 235 
period and each harbored M. haemolytica strains containing resistant genes at the final sampling. 236 
There were 287 isolates of M. haemolytica collected throughout this study including 237 
isolates cultured from samples of both NPS and BAL. Genetic subtype data could not be retrieved 238 
for eleven isolates, leaving the total for analysis at 276 isolates of M. haemolytica. There were 253 239 
isolates of P. multocida and 78 isolates of H. somni included in this descriptive analysis. The 240 
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breakdown of the number of cattle yielding at least one strain of each bacteria are displayed by 241 
time point and sampling source in Table 1. 242 
As reported previously, the 276 isolates of M. haemolytica subjected to WGS fell into one 243 
of two distinct phylogenetic clades and each clade was further divided into subtypes based on 244 
clustering patterns and strong bootstrap support (Figure 1).8 245 
The MIC distributions of all three species of bacteria are presented in Table 2. The MIC 246 
distributions are segregated by on-arrival treatment group assignment and further by whether they 247 
were isolated pre- or post-treatment with gamithromycin. In this table, M. haemolytica MIC 248 
distribution is presented irrespective of genetic subtype.  249 
The cattle that were MM on arrival yielded only a single isolate (2c subtype) displaying 250 
resistance to gamithromycin which was from a calf originating from Missouri which was collected 251 
120 hours after treatment for BRD.  Additionally, the MM cattle had only a single isolate in the 252 
2b subtype. This isolate was cultured prior to treatment and categorized as susceptible with an 253 
MIC of 1 µg/mL, and was negative for the both the erm(42) gene and the msr(E)-mph(E) operon.  254 
Although there are numerical differences in the counts of resistant and intermediate M. 255 
haemolytica between the MM and CON treatment groups, there was no effect of treatment (MM 256 
or CON) observed on the likelihood of isolating a resistant or intermediate M. haemolytica 257 
(P=0.41). There was, however, an observed effect of sampling time point on the likelihood of 258 
isolating intermediate or resistant M. haemolytica (P<0.001). Samples obtained from either NPS 259 
or BAL at 120 hours after treatment administration were more likely to contain resistant or 260 
intermediate isolates as compared to those obtained at time 0 (OR=1,580, 95% CI 173-14,412; 261 
P<0.001). However, samples obtained at 12 hours post treatment administration were not 262 
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significantly different than those obtained prior to treatment (OR=11, 95% CI 0.61-201; P=0.10) 263 
in regards to the likelihood of culturing resistant or intermediate isolates of M. haemolytica.  264 
There was a significant effect of state of origin (P<0.001) on the likelihood of culturing a 265 
resistant or intermediate isolate of M. haemolytica. Calves originating from Tennessee were more 266 
likely (OR=14, 95% CI 0.56-374; P=0.11) to yield a resistant or intermediate M. haemolytica 267 
isolate as compared to calves from Missouri, albeit not a significant difference. Calves originating 268 
from Kentucky were significantly more likely (OR=446, 95% CI 47-4,232; P<0.001) to yield a 269 
resistant or intermediate isolate as compared to calves from Missouri. 270 
No statistical differences were found between treatment groups in regards to the likelihood 271 
of isolating an intermediate or resistant P. multocida (P=0.91) and there was no observed effect of 272 
sampling time point (P=0.50). Models in which state of origin was included did not converge for 273 
P. multocida. Due to the low isolation counts, all attempts at models for H. somni were 274 
unsuccessful. 275 
The majority of the isolates displaying resistance following treatment for BRD with 276 
gamithromycin came from three CON cattle (Table 3). Eighty-six of the 89 (96.6%) post-treatment 277 
isolates in the CON group categorized as resistant came from the 2b subtype and all of these 278 
resistant 2b isolates came from the same pen of cattle, originating from Kentucky. The three 279 
isolates not from the 2b group which displayed phenotypic resistance in CON cattle were isolated 280 
from cattle originating from the states of Missouri (1f), Tennessee (1i), and Kentucky (2d), 281 
respectively. Just a single isolate, M. haemolytica subtype 2c, displayed resistance in MM cattle.  282 
Table 4 displays each M. haemolytica genetic subtype by MIC and the presence or absence 283 
of the macrolide resistance genes within each subtype. All isolates collected in this study were 284 
negative for the presence of the erm(42) gene. The only isolates in which the msr(E)-mph(E) 285 
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operon were detected were in the 2b subtype; all of the cattle yielding these isolates originated 286 
from Kentucky and the isolates displayed phenotypic resistance of MIC ≥16 µg/mL. All 2b isolates 287 
collected prior to treatment had an MIC of 1 µg/mL and were negative for the msr(E)-mph(E) 288 
operon. Eighty-five of 88 (96.6%) of the 2b subtype isolates collected after treatment with 289 
gamithromycin contained the msr(E)-mph(E) operon.  290 
 Discussion 291 
 Isolation of specific bacterial BRD pathogens from NPS prior to treatment, expressed as a 292 
percentage of cattle from which at least one isolate was recovered were 38% for M. haemolytica, 293 
and 65% for P. multocida. These percentages are similar to a previous publication, which reported 294 
45% and 57% isolation of M. haemolytica and P. multocida from NPS samples taken prior to 295 
treatment.29 In 1991, researchers used NPS and BAL samples to compare the flora of the upper 296 
and lower respiratory tract of feedlot cattle undergoing naturally occurring BRD.2 They reported 297 
isolation of 32%, 47%, and 7% from the NPS and 12%, 43%, and 5% from the BAL fluid for M. 298 
haemolytica, P. multocida, and H. somni, respectively. In a nearly identical study published the 299 
following year, they reported isolation of 15%, 70%, and 10% from the NPS (estimated from 300 
graphical data) and 14%, 68%, and 12% from the BAL fluid for M. haemolytica, P. multocida, 301 
and H. somni, respectively.1 The findings from those two studies are similar in regards to the 302 
isolation of both M. haemolytica and P. multocida in the study reported here (Table 1). The 303 
isolation percentage reported herein for H. somni, from both NPS and BAL is slightly higher than 304 
those found previously.1,2 The differences in H. somni isolation percentages could be due to 305 
changes in culture techniques or represent a truly different prevalence of that bacteria species 306 
between the two studies. 307 
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 In the study reported here, the observed effect on resistance phenotype, after administering 308 
a macrolide antimicrobial for the control of BRD on arrival versus controls was not as expected. 309 
Comparing the resistance counts in M. haemolytica isolates pre- and post-treatment between MM 310 
and CON treatment groups; there appeared to be a protective effect of MM with gamithromycin 311 
in regards to the lower total number of resistant isolates in MM cattle. However, when accounting 312 
for clustering of cattle within pen there was not a statistical difference between treatment groups 313 
(P = 0.41). In contrast, there was a numerically higher number of strains displaying resistance in 314 
both P. multocida and H. somni in the cattle that received MM on arrival to the feedlot. However, 315 
there was not a statistical difference between treatment groups (P = 0.91) for P. multocida. 316 
Statistical models for H. somni would not converge due to limited sample size. 317 
 There was a significant difference by state of origin in the likelihood of obtaining a resistant 318 
or intermediate isolate of M. haemolytica. Cattle originating from Kentucky were significantly 319 
more likely to yield a resistant or intermediate isolate as compared to cattle sourced from either 320 
Missouri or Tennessee. Although not statistically significant, cattle from Tennessee tended to be 321 
at an increased likelihood of yielding resistant or intermediate isolates as well. Reasons for this 322 
geographical trend are not clear but could include different management practices or antimicrobial 323 
usage patterns prior to the cattle being marketed and subsequently included in this study. 324 
Comparing only the MIC distributions of the isolates collected post-treatment between the 325 
MM and CON cattle (Table 2); treatment for BRD appeared to increase the prevalence of 326 
phenotypic resistance in M. haemolytica isolated from CON cattle, and increase the prevalence of 327 
phenotypic resistance in P. multocida and H. somni isolated from MM cattle. It should be 328 
mentioned that the post-treatment samples were collected at three different time points and lumped 329 
together for the results and discussion. Additionally, while all 26 cattle had NPS pre-treatment, 330 
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only nine BAL samples were collected pre-treatment and 26 post-treatment. These factors could 331 
possibly confound the results in this study since there were more opportunities for isolation of 332 
resistant (or susceptible) bacteria across these three post-treatment time points. However, it is 333 
interesting to note that the observed increase of phenotypic resistance in P. multocida and H. somni 334 
did not result in numerous overt clinical failures. This is further evidence of a possible disconnect 335 
between in vitro testing results and treatment outcome, especially as it pertains to the macrolide 336 
class of antimicrobials, as has been previously reported.3,20,23 337 
 A single M. haemolytica subtype (2b) represented all genotypic macrolide resistance and 338 
95.6% (86/90) of phenotypic resistance. Nearly ninety-nine percent (89/90) of the phenotypic 339 
resistance in M. haemolytica came from CON cattle. Just one single strain, of the 2c subtype, 340 
phenotypically expressed resistance among the isolates from the MM cattle and this strain did not 341 
harbor macrolide resistance genes. This is suggestive of a possible protective effect of 342 
gamithromycin administration for the control of BRD, in terms of the very low prevalence of 343 
resistance for M. haemolytica observed in the MM group. There is no clear explanation as to the 344 
over-representation of M. haemolytica resistance observed in the CON cattle. Perhaps there is a 345 
synergism between gamithromycin and the immune system (or other factors) when administered 346 
as a MM on arrival (i.e. to a non-clinical animal) that is not present when a calf becomes morbid 347 
with symptoms of BRD.  348 
Macrolides are known to possess anti-inflammatory and immunomodulatory effects in 349 
addition to their antimicrobial activity.4,20 While no such data are available on gamithromycin, 350 
another veterinary macrolide has been extensively studied in this area.11,14-17 Additionally, 351 
azithromycin, a macrolide of the same subclass as gamithromycin, has been shown to exert anti-352 
inflammatory properties on lung epithelial cells in humans.21 Researchers have noted that the 353 
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administration of azithromycin to healthy human volunteers resulted in acute stimulation of 354 
neutrophil degranulation and phagocytosis-associated oxidative burst together with increases in 355 
serum interleukin-1β which the authors stated may contribute towards its antimicrobial activity.5 356 
However, if credibility is given to these immunomodulatory activities as to 357 
gamithromycin’s effect on M. haemolytica, it appeared to have no effect in regards to reducing the 358 
burden of resistance due within P. multocida and H. somni when administered to asymptomatic 359 
cattle on arrival to the feedlot in this study. In fact, a greater proportion of the isolates collected 360 
from MM cattle were resistant to gamithromycin both pre- and post-treatment than those in the 361 
CON group. The P. multocida and H. somni resistant isolates originated from 12 animals, of which 362 
just two were ultimately deemed first-treatment failures and 10 were successes.  363 
 A further intriguing observation from this study is the inability to find M. haemolytica 364 
isolates containing macrolide resistance genes in any samples cultured prior to treatment for BRD 365 
(Table 4), especially considering that nine of the 26 cattle had previously received a macrolide 366 
class antimicrobial as a MM for control of BRD. One conventional theory is that bacteria may 367 
contain the genetic machinery for resistance but not express it phenotypically until after selection 368 
pressure is applied (antimicrobial administration), allowing the proliferation of the resistant 369 
bacterial strains. However, we observed no macrolide resistance genes in pre-treatment isolates 370 
(from both MM and CON cattle). Yet in isolates of M. haemolytica that were collected after the 371 
antimicrobial was administered for treatment of BRD, we observed the presence of the msr(E)-372 
mph(E) operon in 85 of 88  (96.6%) of the 2b subtype. It remains unclear as to why just one 373 
particular subtype contained the macrolide resistance genes and all of the others did not. 374 
This finding could support multiple hypotheses. It is possible that a small population of M. 375 
haemolytica strains were present containing the macrolide resistance genotype that were not 376 
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successfully cultured because of being below a minimum level of detection out competed by more 377 
metabolically fit bacteria, or that the strains harboring the resistance genes were present in refugia, 378 
within biofilms or as persister cells, or present in an area of the respiratory tract not sampled. 379 
Additionally, it is possible that there were no M. haemolytica strains present containing the 380 
resistance genes prior to treatment and they were quickly acquired by horizontal transfer from 381 
other bacterial cells such as P. multocida, as described by Michael et al. in 2011.26 382 
As discussed in the introduction, a previous report has investigated the effects of erm(42) 383 
and msr(E)-mph(E) on the MIC range of gamithromycin and tildipirosin24. They reported that 384 
erm(42), when present in M. haemolytica alone increased the MIC from 0.5 to 4 µg/mL and the 385 
combination of erm(42) and msr(E)-mph(E) resulted in an MIC increase from 0.5 to as high as 32-386 
64 µg/mL for gamithromycin. They found similar distinct increases in MICs to tildipirosin when 387 
isolates contained the macrolide resistance gene erm(42). Other researchers have also observed 388 
dramatic increases in MICs for isolates harboring the macrolide resistance genes erm(42) and 389 
msr(E)-mph(E) for erythromycin, tilmicosin, and tulathromycin.9,19,22_ENREF_7 While MIC data 390 
for these other macrolides were not determined in the study reported here, a similar increase in 391 
MICs to each of those antimicrobials for the isolates containing the macrolide resistance genes 392 
would be expected. Further, given prior evidence of macrolide cross-resistance10,19,30,31 and the 393 
fact that resistance to tulathromycin was observed in BRD isolates prior to it being licensed for 394 
use27 also substantiate an expectation of macrolide cross-resistance in the isolates from this study. 395 
Recent studies reported finding erm(42) and msr(E)-mph(E), being carried in M. 396 
haemolytica isolates independent from one another, very infrequently.24 In this study no isolates 397 
contained the erm(42) gene, however, the msr(E)-mph(E) genes were found frequently in the 2b 398 
subtype of M. haemolytica isolates. Although the maximum antimicrobial test concentration was 399 
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16 µg/mL for MIC testing of gamithromycin, this study demonstrated that the presence of msr(E)-400 
mph(E) alone can increase the MIC of M. haemolytica to gamithromycin from 1 to ≥16 µg/mL for 401 
the 2b subtype. 402 
As reported previously, the culture of a resistant pathogen did not seem to associate with 403 
an increase chance of treatment failure for the cattle in this study.7 Additionally, a nearly 50% 404 
reduction in morbidity was observed subsequent to administration of gamithromycin for control 405 
of BRD along with a 77.8% first treatment response following treatment for BRD with 406 
gamithromycin.7 Other researchers have similarly observed a poor correlation between phenotypic 407 
macrolide resistance and BRD treatment outcome following administration of a macrolide class 408 
antimicrobial.23  409 
 Conclusions 410 
The objectives of this publication were to observe and describe the effect of gamithromycin 411 
administration for both the control and treatment of BRD on the resistance patterns of M. 412 
haemolytica, P. multocida, and H. somni. The results indicate a very complex, and perhaps 413 
bacterial species dependent, interaction is taking place between the host, the bacterial pathogen, 414 
and the antimicrobial. Further, this interaction appears to be confounded by the state from which 415 
the cattle originate. The geographical trend observed in this study deserves further attention to 416 
determine what management practices might cause such a difference. 417 
The M. haemolytica subtype 2b was the only strain to display genotypic resistance to 418 
gamithromycin in this study. Despite the findings of genotypic resistance, a high likelihood of 419 
first-treatment success was observed following administration of gamithromycin for the treatment 420 
of BRD and overt clinical failure did not seem to be associated with the macrolide resistance genes 421 
identified. 422 
132 
 
Future studies aimed at further investigating the prevalence and incidence of resistance and 423 
its correlation with M. haemolytica subtype could lead to the development of a subtype specific 424 
vaccine if a suitable epitope was discovered. If an efficacious vaccine could be developed against 425 
a strain of M. haemolytica that is predisposed for antimicrobial resistance it would be a major 426 
advancement in the area of BRD prevention and therapy. 427 
Additional studies to elucidate the relationships between phenotypic and genotypic 428 
resistance and clinical response to antimicrobials are necessary to inform judicious use of 429 
antimicrobials in the context of relieving animal disease and suffering. 430 
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 Figures and Tables 449 
 450 
Table 5.1 – Number of cattle for which at least one strain of the respective bacteria was isolated 451 
(% of cattle sampled), by time point following diagnosis of bovine respiratory disease. The bottom 452 
row represents the number of cattle sampled at each time point for each sampling source 453 
(nasopharyngeal swab or bronchoalveolar lavage fluid). 454 
 Nasopharyngeal swab Bronchoalveolar lavage fluid 
0 hr 12 hr 24 hr 120 hr 0 hr 12 hr 24 hr 120 hr 
Mannheimia haemolytica 
10 
(38%) 
3 
(33%) 
0 
(0%) 
9 
(35%) 
2 
(25%) 
2 
(22%) 
0 
(0%) 
6 
(23%) 
Pasteurella multocida 
17 
(65%) 
5 
(56%) 
4 
(44%) 
8 
(31%) 
4 
(50%) 
6 
(67%) 
1 
(11%) 
6 
(23%) 
Histophilus somni 
8 
(31%) 
0 
(0%) 
1 
(11%) 
1 
(4%) 
2 
(25%) 
0 
(0%) 
1 
(11%) 
2 
(8%) 
Cattle sampled (n) 26 9 9 26 8 9 9 26 
 455 
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Table 5.2 - MIC to gamithromycin of M. haemolytica (n = 276), P. multocida (n = 253), and H. somni (n = 78) isolated from cattle 
(n=26) diagnosed with bovine respiratory disease prior to treatment (Pre-Tx) and a summation of isolates collected at 12, 24, and 120 
hours following treatment (Post-Tx) with gamithromycin. Distribution is further divided by treatment group, either those receiving mass 
medication (n = 9 cattle) or control (n = 17 cattle). Isolates were cultured from either deep nasopharyngeal swabs or from fluid recovered 
from bronchoalveolar lavage and represent several isolates per calf.* 
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 Minimum Inhibitory Concentration (µg/mL) 
≤0.03 0.06 0.12 0.25 0.5 1 2 4 8 ≥16 
C
o
n
tr
o
l 
(n
 =
 1
7
) 
Mannheimia haemolytica 
Pre-Tx - - - - - 89 2 - - 1 
Post-Tx - - - - - 46 - - 11 88 
Pasteurella multocida 
Pre-Tx - - - 1 33 17 - - - 1 
Post-Tx - - - - 19 8 - - - 2 
Histophilus somni 
Pre-Tx - 3 6 37 1 1 - - - 1 
Post-Tx - - - - - - - - - - 
M
a
ss
 M
ed
ic
a
ti
o
n
  
(n
 =
 9
) 
Mannheimia haemolytica 
Pre-Tx - - - - - 26 - - - - 
Post-Tx - - - - - 10 1 1 - 1 
Pasteurella multocida 
Pre-Tx - - - - - - - - 1 49 
Post-Tx - - - - 1 - - - - 121 
Histophilus somni 
Pre-Tx - - - - - - - - - 6 
Post-Tx - - - - - - - - - 23 
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Table 5.3 –MIC to gamithromycin of M. haemolytica isolates (n=276) from either the control 
group (CON) or those cattle that were mass medicated (MM) with gamithromycin on arrival. 
Isolates are grouped by subtype and collection time point; (Pre-Tx = collection just before 
treatment with gamithromycin for BRD, Post-Tx = collection at either 12, or 120 hours following 
gamithromycin treatment for BRD).  No M. haemolytica isolates were obtained at 24 hours 
following treatment.* 
 Minimum Inhibitory Concentration (µg/mL) 
Treatment Subtype Time 
Point 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 ≥16 
CON 1e Pre-Tx - - - - - 2 2 - - - 
Post-Tx - - - - - - - - - - 
1f Pre-Tx - - - - - 11 - - - 1 
Post-Tx - - - - - 19 - - - - 
1i Pre-Tx - - - - - 12 - - - - 
Post-Tx - - - - - 19 - - - 1 
2b Pre-Tx - - - - - 42 - - - - 
Post-Tx - - - - - 2 - - - 86 
2d Pre-Tx - - - - - 22 - - - - 
Post-Tx - - - - - 6 - - 11 1 
MM 1c Pre-Tx - - - - - 1 - - - - 
Post-Tx - - - - - - - - - - 
2b Pre-Tx - - - - - 1 - - - - 
Post-Tx - - - - - - - - - - 
2c Pre-Tx - - - - - 24 - - - - 
Post-Tx - - - - - 10 1 1 - 1 
*Pre-Tx = Pre-treatment; Post-Tx = Post-treatment; CON = control treatment group; MM = mass 
medication with gamithromycin 
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Table 5.4 – MIC of M. haemolytica isolates (n=276) collected either prior to treatment for BRD 
with gamithromycin (Pre-Tx) or at 12, or 120 hr post treatment (Post-Tx). Isolates of the subtype 
2b were the only isolate subtype that displayed msr(E)-mph(E) at any point during collection. No 
M. haemolytica isolates were obtained at 24 hours following treatment.* 
 Minimum Inhibitory Concentration (µg/mL) Gene Presence 
Time Point Subtype 0.03 0.06 0.12 0.25 0.5 1 2 4 8 ≥16 erm(42) 
msr(E)-
mph(E) 
Pre-Tx 1c - - - - - 1 - - - - N N 
1e - - - - - 2 2 - - - N N 
1f - - - - - 11 - - - 1 N N 
1i - - - - - 12 - - - - N N 
2b - - - - - 43 - - - - N N 
2c - - - - - 24 - - - - N N 
2d - - - - - 22 - - - - N N 
Post-Tx 1f - - - - - 19 - - - - N N 
1i - - - - - 19 - - - 1 N N 
2b 
  
- - - - - 2 - - - 1 N N 
- - - - - - - - - 85 N Y 
2c - - - - - 10 1 1 - 1 N N 
2d - - - - - 6 - - 11 1 N N 
*Pre-Tx = Pre-treatment; Post-Tx = Post-treatment; N = No; Y = Yes 
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Figure 5.1 – Neighbor-Joining trees of M. haemolytica clades 1 and 2 based on genome wide 
concatenated SNPs.  Subtypes within the clades are denoted by lower case letters.  Numbers beside 
internal nodes of the tree represent bootstrap percentage values from 100 pseudo alignments.  The 
scale bar represents substitutions per site within trees.  The genetic distance between clades 1 and 
2 exceeds the genetic distance within the clades and is not shown. 
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Chapter 6 - In vitro characterization of gamithromycin antibacterial 
activity against both susceptible and resistant M. haemolytica 
 
 
ABSTRACT 
 Bacterial pathogen sensitivity to antimicrobials is most often assessed by determining the 
minimum concentration of a given antimicrobial that will visibly inhibit growth in vitro after 18-
24 hours of incubation, termed the minimum inhibitory concentration (MIC). However, this assay 
fails to capture the interaction of the antimicrobial and the pathogen over the course of time which 
is an important aspect in the host-pathogen-drug interaction. Time-concentration killing assays are 
another type of in vitro experiment that can be used to describe a drug’s antibacterial effects over 
time. Given that, the objectives of this study were to: (1) perform in vitro time-kill curve studies 
with gamithromycin on genetically subtyped clinical isolates of M. haemolytica that have been 
previously identified as either resistant or susceptible, (2) determine the concentrations at which 
gamithromycin demonstrates activity at the two levels of antibacterial action (bacteriostasis and 
bactericidal) for future PK-PD modeling and integration of gamithromycin. Gamithromycin 
exhibited both bactericidal and bacteriostatic activity against M. haemolytica depending on the 
concentration of drug. Further, antibacterial activity was observed against highly resistant M. 
haemolytica isolates but this activity was at concentrations above those likely unattainable in vivo.  
  
INTRODUCTION 
 The determination of pathogen susceptibility to an antimicrobial is conventionally done 
through minimal inhibitory concentration (MIC) testing. The MIC is the minimum concentration 
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of a given antimicrobial that will visibly inhibit growth in vitro after 18-24 hours of incubation, 
which may be viewed as a pharmacodynamic estimate1-3. After an MIC is determined, the value 
can be compared to breakpoint values established by the Clinical and Laboratory Standards 
Institute Veterinary Antimicrobial Susceptibility Testing Subcommittee (CLSI/VAST) for the 
categorization of susceptible, intermediate, or resistant.  
The main advantage of the MIC determination procedure is that it is relatively easy to 
determine experimentally and an organism that is cultured can be rapidly defined as either 
susceptible, intermediate, or resistant, given that CLSI criteria have been established for the 
specific pathogen / antimicrobial / disease / host species / dose regimen combination. The main 
disadvantage of the MIC is that it is determined from a single static measurement at the end of the 
experiment and it therefore, inherently ignores the interaction of the drug and pathogen over the 
course of time3. A more complete approach involves an investigation of the pharmacodynamic 
nature of an antimicrobial through in vitro exposure of exponentially growing bacteria to a range 
of static drug concentrations with bacterial counts being monitored over the time course of the 
experiment, also called a time-concentration kill (TCK) curve experiment. The quantification of 
growth at numerous time points across the dilution range of drug over the 24 hour incubation 
period permits the determination of antimicrobial and bacterial interaction dynamics. These 
experiments can be used to determine if an antimicrobial is bacteriostatic or bactericidal and the 
speed at which the bacteria are killed. Additionally, TCK curve experiments allow for the 
development of a pharmacodynamic model that when linked with a pharmacokinetic and statistical 
model can be used to select optimal antimicrobial dosing strategies which may then be tested in 
clinical trials4.  
A major food animal disease which could benefit from these types of investigations is 
bovine respiratory disease (BRD), a disease of significant concern for both the beef and dairy 
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industry in regards to animal welfare and economic impacts.  The three most commonly cited 
bacterial pathogens involved in BRD are Mannheimia haemolytica, Pasteurella multocida, and 
Histophilus somni5. Antimicrobial resistance appears to be increasing in populations of these 
pathogens within some populations of cattle6, and the need for advanced understanding of optimal 
dosing regimens to achieve bacteriological cure and minimize selection for resistant target 
pathogens is paramount. The use of PK-PD integration and modeling in the selection of dosing 
regimens for the treatment of BRD have been previously performed for danofloxacin7, 
marbofloxacin8, florfenicol9,10, and amoxicillin11. Time-kill curve experiments, performed solely 
as investigations into antimicrobial potency and kill rate, have been previously reported for several 
antimicrobials against the pathogens of BRD12-15. However, in all of the aforementioned 
publications, the bacterial isolates were categorized as susceptible to the antimicrobial used in that 
experiment which may not always be the case in the field. 
An example of an antimicrobial class where the classically cited pharmacodynamic 
properties may not be universally agreed upon is the macrolides.  Antimicrobials of this class 
inhibit RNA-dependent protein synthesis through a reversible binding to the 23S ribosomal RNA 
in the 50S subunit of the bacterial ribosome16. Generally speaking, antimicrobials that interfere 
with protein synthesis are considered bacteriostatic. However, macrolides have been shown to be 
both bactericidal and bacteriostatic depending on the concentration of the drug and the particular 
bacterial species exposed16.  
Gamithromycin is a semi-synthetic, 15 member-ring macrolide of the azalide subclass that 
is licensed in the United States for the treatment and control of bovine respiratory disease (BRD)17. 
It has demonstrated efficacy as an antimicrobial for both the prevention and treatment of BRD18-
20. The antibacterial activity of gamithromycin against BRD pathogens has been investigated12. 
Gamithromycin demonstrated bactericidal activity (3 log kill within 24 hours) against both M. 
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haemolytica and P. multocida at MIC values as high as 4 µg/mL and bacteriostatic activity against 
H. somni at the MIC90 concentration of 0.5 µg/mL. Given this previous work, the objectives of this 
experiment were to: (1) perform in vitro time-kill curve studies with gamithromycin on genetically 
subtyped clinical isolates of M. haemolytica that have been previously identified as either resistant 
or susceptible, (2) determine the concentrations at which gamithromycin demonstrates activity at 
the two levels of antibacterial action (bacteriostasis and bactericidal) for future PK-PD modeling 
and integration of gamithromycin. 
MATERIAL AND METHODS  
Animals, BRD diagnosis, sample collection, and treatment administration 
 This study was approved by the Kansas State University Institutional Animal Care and Use 
Committee. As part of another study, 180 head of feeder cattle (165-269 kg) were sourced from 
three separate auction markets within the United States and brought to a research feedlot in 
Manhattan, KS21. The cattle were randomly allocated to treatments as described in that manuscript, 
placed in pens according to treatment, and observed for 28 days for symptoms consistent with 
BRD. The diagnosis of BRD was performed by a veterinarian masked to treatment allocation with 
the use of an objective scoring system and rectal temperature criteria. At the time of BRD diagnosis 
cattle were treated with gamithromycin according to label directions (6 mg/kg, single subcutaneous 
injection). Samples were collected for aerobic bacterial culture from both deep nasopharyngeal 
swabs and bronchoalveolar fluid (BAL) at several possible time points around the time of 
treatment, and then again 120 hours after treatment. Additionally, samples were harvested at the 
same time points for the determination of gamithromycin concentrations in both plasma and 
pulmonary epithelial lining fluid (PELF).  
Bacterial isolation, MIC determination, and M. haemolytica phylogenetic analysis 
Nasopharyngeal swab and PELF samples from cattle morbid with BRD were hand 
delivered to the laboratory where they were plated directly onto trypticase soy + 5% blood, 
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chocolate, and MacConkey agar plates. The plates were incubated in 5% CO2 at 37˚C for 18 to 24 
hours and as many as 12 individual colonies displaying growth characteristics typical of M. 
haemolytica were further isolated in pure culture from each calf. The identity of each isolate was 
confirmed with MALDI Biotyper® (Bruker Daltonics, Billerica, MA, USA) and frozen for later 
susceptibility testing. 
The gamithromycin MIC was determined for each isolate by personnel masked to treatment 
group based on a broth microdilution technique utilizing Staphylococcus aureus ATCC 29213 for 
quality control, as previously described21. Determination of susceptible (≤4 µg/mL), intermediate 
(8 µg/mL) or resistant (≥16 µg/mL) was based on clinical breakpoints established for 
gamithromycin by CLSI (personal communication with co-author RKT). 
Briefly, as previously reported, DNA was extracted, quantified, and Illumina Nextera XT 
DNA libraries were constructed and sequenced (minimum 10X genome coverage). The library 
sequences were individually mapped to an available closed circular M. haemolytica genome 
publicly available in GenBank (CP004752)22,23. Bootstrapped Neighbor-Joining phylogenetic 
trees were constructed from SNP genotypes to compare genetic relatedness of individual isolates 
of M. haemolytica. 
Selection of isolates 
 In total, 276 isolates of M. haemolytica were obtained over the course of the clinical portion 
of the study. Following the determination of an MIC for each isolate, six susceptible isolates (MIC 
= 1.0 µg/mL) and five resistant isolates (MIC ≥16.0 µg/mL) were selected for the in vitro TCK 
curve experiments. The five resistant isolates were discovered to have an actual MIC of 128 µg/mL 
(vide infra) and will be discussed as such from this point forward. Isolates were selected from a 
genetically diverse population to evaluate if there were detectable differences in the antimicrobial 
activity between strains.  
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In vitro time-concentration kill curve experiments 
 The M. haemolytica strains used in this study were part of a collection of strains described 
previously23,24. Strains were revived from banked samples on Chocolate agar (Hardy Diagnostics, 
Santa Maria, CA, USA) at 37°C with 5% CO2, for 18-20 h. Individual colonies were selected and 
struck for isolation onto Mueller-Hinton II (MHII) agar (Becton, Dickinson and Co, Sparks, MD 
USA) and incubated at 37°C for 18-20 h. The resulting cultures were used as the inoculum for the 
TCK assays described below.  
Six isolates in the MIC = 1 µg/mL range and 5 isolates in the 128 µg/mL MIC range were 
selected for TCK analysis. Isolates were selected with the goal of capturing the genetic diversity 
of M. haemolytica present in the strain collection. Accordingly, susceptible isolates included 
representatives of subtypes 1c, 1e, 1f, 1i, and two isolates of the 2b subtype24. All resistant isolates 
originated from a single subtype (2b); care was taken to select isolates from different animals and 
different study time points.  
Two different stock concentrations of gamithromycin were prepared for the TCK assays, 
one at 5120 µg/mL, which was used for the low range assays (for isolates with MIC = 1 µg/mL), 
and the other at 10,240 µg/mL, which was used for high range assays (for isolates with MIC 128 
µg/ml). For each stock solution the appropriate amount of gamithromycin powder was dissolved 
in 0.1M sodium phosphate buffer, pH 6.0. Stock solutions were distributed into 1 mL aliquots 
which were stored at -80°C, and used within one month of preparation. For low range assays, 
dilutions of gamithromycin ranged from 0.25 to 16 µg/mL (equivalent to 0.25 – 16 x MIC) in a 3 
mL assay volume. For high range assays dilutions ranged from 4 - 256 µg/mL (equivalent to .03 
– 2 x MIC, for MIC = 128 µg/mL).  
For each strain to be assayed, bacterial cultures were prepared by transferring 3 to 5 
colonies from a fresh MHII agar plate to 5 mL sterile ddH2O, until the turbidity was equivalent to 
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a 0.5 McFarland standard.  From this suspension, 350 µL was transferred to 5 mL of Mueller-
Hinton II (MHII) broth (Becton, Dickinson and Co, Sparks, MD USA) and then 150 µL of the 
resulting suspension was used to inoculate 30 mL of MHII broth that had been pre-warmed to 
37°C. The 30 mL cultures were incubated without shaking, at 37°C for 2h, and the resulting 
cultures were primed to enter log-phase growth, with starting concentrations of approximately 1 – 
3 x 105 CFU/mL. Time-concentration kill assays were performed using 48 well, deep-well blocks, 
with 2.9 mL of each 30 ml culture placed in each of 8 wells. This design allowed two strains to be 
tested against 8 concentrations of antibiotic, in biological triplicate, in each 48 well block.  
Assays were conducted using a multichannel pipette and were initiated by the addition of 
100 µl of the appropriate stock concentration of antibiotic (0 to 480 µg/mL for a working 
concentration range of 0 to 16 µg/mL (low range assay); or 0 to 7680 µg/mL for a working 
concentration range of 0 to 256 µg/mL (high range assay). Samples were mixed by repeated 
pipetting (7 - 9 times) and tips were changed between biological replicates. Nine time points were 
evaluated for each assay, including 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 h, and the sample block was 
incubated at 37°C with shaking for the duration of the assay. At each time point, 100 µL was 
removed from each well and subjected to serial decimal dilutions. Viable cell counts were 
determined using the “track dilution” plating method25, which entailed spotting 15 µL of each 
appropriate dilution to a MHII agar plate. Inoculated plates were then tilted at a 45° angle, allowing 
the sample to migrate in a track to the opposite side of the plate. With a 15 µl plating volume, the 
lower limit of detection (LOD) of this plating method is log10 1.83 or approximately 67 CFU/mL. 
All plates were held at room temperature from time point 0 to 8, after which they were 
inverted and incubated at 37°C for 14 – 16 h. Throughout the assay, the plated dilutions targeted 
a viable cell count of 20 to 200 CFU per track.  Staphylococcus aureus ATCC 29213 served as a 
quality control strain for concentrations of gamithromycin in the low range assay and for the high 
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range assay, antibiotic solutions were diluted 1:10 so that values fell within the assayable range. 
Viable cell counts were recorded and CFU/ml concentrations calculated. All assays were 
performed in biological triplicate and the geometric mean and standard deviation at each time point 
were calculated and plotted. 
Determination of antibacterial activity 
The antibacterial effect of gamithromycin was quantified for two levels of growth 
inhibition for each isolate of M. haemolytica; bacteriostatic and bactericidal activity. The values 
for bacteriostatic and bactericidal activity were defined as the values which produced no change 
from the initial bacterial count and values which provided a 3-log10 reduction in initial inoculum 
count after 24 h incubation, respectively. The LOD of 67 CFU/mL precluded the ability to detect 
the concentration at which bacterial eradication (4-log10 reduction) was attained. 
 
RESULTS 
BRD morbidity 
 As previously reported, 26 of the 180 (14.4%) calves were diagnosed with BRD during the 
28 day study period.21 Nine calves were from the treatment group administered gamithromycin on 
arrival for control of BRD and 17 were from the control group. Four calves were classified as 
treatment failures, two from each treatment group. 
MIC verification 
The MIC of each isolate was verified, in comparison to the previously determined MIC, 
using CML1FZAC plates prior to the TCK assay. The MIC of the resistant isolates, previously 
characterized with MIC of ≥ 16 µg/mL21, were further defined as having an MIC = 128 µg/ml by 
broth microdilution, using a dilution series of gamithromycin ranging from 4 – 256 µg/ml. 
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In vitro time-concentration kill curves 
 The results of the in vitro TCK curves for the isolates with an MIC of 1 (n=6) and 128 
µg/mL (n=5) are illustrated in Figures 1 and 2, respectively. In each assay the bacterial growth was 
as expected in control samples, with an increase in count of ~3- log10 CFU/mL over the incubation 
period of 24 h.  
The isolates with an MIC = 1 µg/mL displayed little growth inhibition at 0.25 and 0.5 
multiples of MIC for the first 4 hours, however these concentrations resulted in 3-log10 reductions 
in counts by 24h of incubation. Concentrations at the MIC (1 µg/mL) resulted in little bacterial 
growth being observed at early time points up to 4h of incubation for five of the six strains. The 
other strain (33204) had 3-log10 increases in CFU/mL up to 4 hours. However, all six strains were 
3-log10 reduced by either 8 (strains 32600, 33204, 32770, 33058, 32917) or 24 hours (strain 33058). 
At the drug concentrations of 8 and 16 × MIC, colony counts were below the LOD after short 
exposure (3 h) to gamithromycin.  
In vitro antibacterial activity of gamithromycin against resistant strains of M. haemolytica 
(MIC = 128 µg/mL) was more limited. There was an increase in bacterial count at 0.03 – 0.12 × 
MIC for all isolates. Isolate 32998 displayed bacteriostasis at 0.25 and 0.5 × MIC. Isolate 32711 
was held static at 0.25 x MIC and approached a 3-log10 decrease in CFU/mL (2.86) at the 0.5 x 
MIC concentration. Paradoxically, isolate 33014 was static at 0.25 x MIC but not inhibitory at 0.5 
x MIC. Gamithromycin was bactericidal for all isolates at 2 x MIC within 3 – 8 hours of incubation.  
Bactericidal activity was obtained at 1  MIC for strains 32711, 33014, and 32998 at 4, 8, and 24 
hours of incubation, respectively. 
Antibacterial activity 
Bactericidal activity was exhibited at 0.25 – 16 multiples of the MIC over the 24 hour 
incubation period for all six MIC = 1 µg/mL isolates of M. haemolytica. In resistant strains (MIC 
= 128 µg/mL), bactericidal activity was obtained for three of five isolates at 1 x MIC and for all 
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five isolates at 2 x MIC. Data from TCK assays demonstrated that isolates at a lower MIC (1 
µg/mL) were killed in an apparent time dependent manner. The antibacterial activity of 
gamithromycin against MIC 128 µg/mL was quite limited in this study due to the concentrations 
tested, however killing appeared to be concentration dependent. 
 
DISCUSSION 
Antimicrobials of the macrolide class have been described as either bacteriostatic or 
bactericidal depending on the concentration and the species of bacteria16. Macrolide class 
antimicrobials were historically grouped with other time-dependent drugs,  implying that the PD 
index of %T>MIC is the parameter best describing their efficacy; however, due to post-antibiotic 
effects, macrolides might be better evaluated with use of the AUC/MIC ratio26.  
 In 2014, Tessman and Bade reported observing a 3-log decrease in CFU/mL of M. 
haemolytica with an MIC of 1 µg/mL at 1 x MIC by 8 hours post gamithromycin exposure with 
an in vitro TCK assay similar to the current study12. Additionally, they found that all of the M. 
haemolytica isolates (n = 5, MIC = 1 µg/mL) they tested resulted in a 3-log decrease at the 4 µg/mL 
concentration by 4 hours (their first quantification time point).  The current study found similar 
results, with five of the six isolates in this study having 3-log10 CFU/mL reductions by 8 hours 
and all six isolates by 24 hours of incubation. The findings from the current study also 
demonstrated a 3-log reduction for all six MIC = 1 µg/mL isolates at 4 x MIC by 8 hours 
incubation. Further, five of the six M. haemolytica isolates resulted in a 3-log decrease at the 4 
µg/mL concentration by 3 hours and all six were reduced by 3-log CFU/mL at 4 hours.  
In the M. haemolytica isolates with an MIC = 1 µg/mL growth inhibition was observed at 
concentrations lower than was expected. In all six strains a 3-log10 decrease in CFU/mL was 
observed by 24 hours indicating that gamithromycin was bactericidal in a time-dependent manner. 
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It is possible that residual gamithromycin from the wells was transferred during the dilution 
procedures leading up to colony forming unit quantification. As another possible explanation for 
these findings, differences between the MIC and TCK assays should be noted. While the media 
composition and temperature of incubation were the same, the inoculum size, media fluid volume, 
and incubation conditions (static incubation for MIC and shaking incubation for TCK) differ 
between the two tests. Additionally, MIC values were determined at 18-20 hours and the final 
quantification point for the TCK assays were performed at 24 hours of incubation. Finally, the 
MIC test outcome is determined by a visual inspection for cell death or growth as compared to the 
TCK where viable cell counts were determined using the track dilution plating method.  
The microbiological assays in this study were limited to in vitro assays for both the MIC 
and TCK analyses. Previous publications have noted differences between broth and serum MIC 
determinations, especially as it pertains to macrolide antimicrobials14,15,27-31. In these studies the 
MIC of macrolides in heat inactivated bovine serum have been decreased as compared to those 
determined in broth. Likewise, studies comparing the killing kinetics of macrolides between in 
vitro and ex vivo assays have found that the kinetics differ in the different media with improved 
killing ex vivo31. It is possible that if ex vivo studies would have been performed the killing kinetics 
of gamithromycin would have differed as well.  
These data are further limited by the relative large gaps in data points for both the time and 
drug concentrations for the TCK curves. There are large changes in bacteria CFU/mL from the 8 
to 24 hour time points, most notably for the susceptible strains. The absence of data to inform the 
killing over that 16 hour time span limits the usefulness of the final data point. Additionally, the 
LOD is too high to quantify the concentration where bacterial eradication might be achieved. 
Finally, the higher dilutions (e.g. 64, 128, and 256 µg/mL) represent large changes in drug 
concentrations making it difficult to determine where the actual MIC is located. Extending the 
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doubling dilution approach in the determination of MIC, as suggested by Aliabadi and Lees (2001 
and 2002),32,33 might be one possible approach to more accurately describe the MIC of the more 
highly resistant strains used in this study. These factors described above present limitations to a 
direct integration into a PK-PD model. 
A disconnect between in vitro MIC determination and BRD clinical case outcome for the 
macrolide antimicrobials has been previously reported21,34 which could possibly be explained by 
the differences between the artificial media and the physiological matrix where the infection 
resides. Activity of gamithromycin against highly resistant isolates (128 µg/mL) presented in this 
study was limited to only those concentrations at or 2 multiples above the MIC. Given the results 
of previous pharmacokinetic data, these concentrations are quite likely physiologically 
unattainable. However, gamithromycin has been demonstrated to be a clinically effective 
antimicrobial at its labeled dosage of 6 mg/kg for both the treatment and control of BRD18,19,35. 
However, this efficacy, in relation to low and high MIC isolates was not determined in the clinical 
trials.   
  These data included herein demonstrate that gamithromycin can be bactericidal or 
bacteriostatic against M. haemolytica depending on the concentration of drug. Additionally, while 
antibacterial activity was observed against highly resistant M. haemolytica isolates (MIC = 128 
µg/mL) it was at concentrations so high (1 – 2 x MIC) as to be physiologically unattainable. 
However, the significance of these findings in light of all of the in vitro, in vivo, and ex vivo 
experimental discrepancies has yet to be determined for the macrolide class of antimicrobials. As 
such, a word of caution must be advised when these type of data are used to make dosage 
predictions for clinical use in the treatment of BRD. 
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Figure 2 – In vitro inhibition of growth of six different strains of M. haemolytica (MIC = 1 µg/mL) 
over 24 hour exposure to 8 MIC multiples of gamithromycin. SEM bars not included for clarity of 
graphics. (Lower limit of detection 67 CFU/mL) 
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Figure 3 – In vitro inhibition of growth of six different strains of M. haemolytica (MIC = 128 
µg/mL) over 24 hour exposure to 8 MIC multiples of gamithromycin. SEM bars not included for 
clarity of graphics. (Lower limit of detection 67 CFU/mL) 
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Chapter 7 - Consideration for future studies 
 
Our work has built upon techniques utilized for many years in the human medical research 
field and applied them to naturally occurring BRD. The use of naturally occurring BRD was a 
more clinically relevant approach yet much more difficult to perform due to not having control 
over the sample size. The lack of power potentially precluded our research from reaching more 
definitive answers but led to many new hypothesis which can be built upon in the future.  
 Considering the ability of an Integrative Conjugative Element (ICE), conferring resistance 
to multiple antimicrobials, to travel amongst members of the Pasteurellaceae family (and to many 
other bacteria), a similar approach to characterizing the resistance genes for both P. multocida and 
H. somni would be of great value. Additionally, repeating the same PK-PD approaches utilized for 
M. haemolytica for both P. multocida and H. somni would add a tremendous amount of knowledge 
to this area. 
Of great personal interest to me are the macrolide antimicrobial compounds. The apparent 
disconnect between the results of in vitro testing methods (MIC, TCK, etc.) and clinical outcome 
data are particularly intriguing. All of the work contained herein was performed purely in vitro. 
However, ex vivo methods have been shown by some research teams to more closely resemble the 
observed treatment outcome (i.e. ex vivo analysis often result in lower MIC values than in vitro 
methods for macrolide compounds). Finally, the anti-inflammatory and immunostimulatory 
abilities of macrolides are particularly fascinating to me and as I learn more about the work that 
has been done in this area it raises the question of how much of a role those properties are 
contributing to clinical outcome as well. 
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 Conclusions 
Currently, by some accounts, we, as a group of human and veterinary health care 
professionals, are in crisis mode in regards to the increasing appearance of antimicrobial resistance 
and the lack in the discovery of novel classes of antimicrobial compounds. At no point before have 
clinicians been faced with a more difficult decision when deciding whether to treat with an 
antimicrobial or allow an animal to attempt a self-cure. Numerous organizations have released 
consensus statements and/or prescription guidelines in an attempt to persuade the general 
practitioner to judiciously use antimicrobials. It will take the work of many different types of 
scientists working in conjunction with the clinicians practicing in the field to truly make a 
difference in fine tuning the treatment regimens that can both successfully treat an infectious 
disease and mitigate the risk of antimicrobial resistance.   
The ability with which we were able to integrate so many researchers with different areas 
of expertise in this work certainly helped to make this project a success. Future work should 
likewise pull together different research teams for collaborative synergism and novel approaches 
to the same ultimate end goal. 
